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ABSTRACT OF DISSERTATION

REGULATION OF UV-PROTECTIVE PATHWAYS DOWNSTREAM OF THE
MELANOCORTIN 1 RECEPTOR IN MELANOCYTES
Malignant cutaneous melanoma is the deadliest form of skin cancer, and a majority
of melanoma diagnoses are a result of exposure to ultraviolet (UV) radiation. UV
radiation causes DNA damage, which if not repaired correctly via nucleotide
excision repair (NER) can result in mutations and melanomagenesis. The
melanocortin 1 receptor (MC1R) is a Gs protein coupled receptor located on
melanocyte plasma membranes and is involved in protecting the skin from UV
induced damage. MC1R signaling results in the activation of two protective
pathways: 1) induction of eumelanin synthesis downstream of micropthalmiaassociated transcription factor (MITF) and 2) acceleration of NER downstream of
ataxia telangiectaseia mutated and Rad3 related (ATR). MC1R signaling,
however, also promotes melanocyte proliferation, therefore, the activation of the
MC1R pathway must be regulated. The overall hypothesis of this dissertation is
that the pathways downstream of MC1R can be manipulated to protect against UV
induced damage.
Chapter 2 investigates the regulation of the MC1R neutral antagonist human βdefensin 3 (βD3). UV damage did not induce βD3 mRNA expression in ex vivo
human skin explants. The induction of βD3 expression instead correlated with
inflammatory cytokines including TNFα.
Chapter 3 investigates the interdependence and cross talk between the two
protective pathways downstream of MC1R. We directly tested the effect of MITF
on the acceleration of NER and the effect of ATR on the induction of eumelanin
synthesis following MC1R activation. MITF was not required for the acceleration
of NER as mediated by ATR, however, the induction of transcription of enzymes
involved in eumelanin synthesis was dependent upon ATR kinase activity.
Finally, Chapter 4 investigates the mechanism by which MC1R promoted
proliferation and whether the two UV protective pathways downstream of MC1R
could be selectively activated without the risk of melanocyte proliferation. MC1R

signaling resulted in activation of the mechanistic target of rapamycin complex 1
(mTORC1), a major regulator of cell growth and proliferation. Inhibition of
mTORC1 signaling via rapamycin prevented MC1R induced proliferation in vitro.
Rapamycin, however, did not prevent MC1R induced eumelanin synthesis or the
acceleration of NER in vitro or in vivo suggesting it is possible to selectively activate
the beneficial signaling pathways without the risk of melanocyte proliferation.
The results of this dissertation suggest that MC1R signaling could be augmented
in individuals to prevent UV induced damage.
KEYWORDS: Melanocortin 1 Receptor (MC1R), β-Defensin 3 (βD3),
Micropthalmia-Associated Transcription Factor (MITF), Ataxia Telangiectasia
Mutated and Rad3 Related Protein (ATR), Mechanistic Target of Rapamycin
(mTOR)
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Chapter 1: Introduction
________________________________________________________________
1.1 Melanoma Introduction
Malignant cutaneous melanoma is an aggressive form of skin cancer that is
predicted to affect greater than 76,000 individuals in the United States in 2016
(Howlander et al., 2015). It results from the uncontrolled proliferation of
melanocytes located in the epidermal/dermal junction of the skin. There are two
additional main categories of skin cancer, basal cell and squamous cell carcinoma,
resulting from proliferation of epidermal basal cells or squamous keratinocytes
respectively.
Although cutaneous melanoma is only responsible for a small fraction of the total
cases of skin cancer, because of its aggressive metastatic nature, it causes over
90% of skin cancer related deaths (Howlander et al., 2015). Long-term prognosis
correlates strongly with the stage of disease, and following metastasis, survival
rates markedly decline. If diagnosed while in the early stages, surgical resection is
associated with a nearly 100% five-year survival rate (Howlander et al., 2015;
Schadendorf et al., 2015). If the the disease is not diagnosed early, however, it
has a tendency to metastasize via both hematogenous and lymphatic routes.
Although there has been great progress in treating melanoma utilizing both
targeted molecular and immunotherapies, metastatic melanoma has a tendency
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to recur. In general, the five-year survival rate for late stage metastatic melanoma
is below 20% (Howlander et al., 2015). Early identification and treatment in addition
to prevention are therefore essential clinical tools to minimize mortality.
Melanoma is concerning not only because of its aggressive nature, but also
because its incidence rate has been steadily rising faster than any other cancer
throughout the past century (Linos et al., 2009). In the early 1900’s the lifetime risk
of developing melanoma in the United States was 1 in 1,500, while in 2002, the
lifetime risk had risen to 1 in 62 (Rigel, 2002) (Figure 1.1)1. The incidence rate has
continued to rise since 2002, and for the next decade it increased 1.8% per year,
such that 21.3 per 100,000 individuals were diagnosed with melanoma between
2007 and 2011 (Surveillance, Epidemiology, and End Results April 2014).
The rise in melanoma incidence appears to be multifactorial resulting from
environmental and cultural factors in addition to medical advancements. A
component of the increase is believed to be due to enhanced awareness and
improvements in diagnosis in addition to increased life expectancy (Balducci &
Beghe, 2001). Melanoma incidence increases with advanced age, therefore, as
life expectancy increases, melanoma rates would be predicted to increase as well.
Although it can affect patients of any age, the average age at diagnosis and death
is 62 and 69 years respectively (Surveillance, Epidemiology, and End Results
February 2016). Many studies explain that one of the most important factors in the
rise in incidence is an increase in exposure to ultraviolet (UV) radiation, either solar

1
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Figure 1.1 Lifetime Risk of Developing Melanoma
The lifetime risk of developing melanoma has risen over the past century
from 1/1500 in 1900 to 1/52 in 2011.
(Adapted from Wolf Horrell et al., 2015)
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or artificial. Cutaneous melanoma has a high association with exposure to UV
radiation (further discussed below) and is traditionally found on sun exposed
surfaces (Rigel and Carucci, 2000). The popularization of a tanned physique in
Western cultures beginning in the early 1900’s has led to an increase in intentional
exposure to UV. Behavior modification has proved useful in decreasing incidence
rates in other cancers, for example smoking cessation has led to a reduction in
lung cancer incidence (Henly et al., 2010). Many individuals, however, believe they
look better, feel healthier, and are happier with tanned skin (Balk et al., 2013).
Minimizing UV exposure, therefore, has proved difficult suggesting the need to
enhance innate protective mechanisms in order to prevent UV induced skin
cancer.
1.2 Ultraviolet Radiation
Ultraviolet radiation is believed to be the main extrinsic risk factor associated with
development of melanoma, with one study reporting over 80% of melanoma
diagnoses being related to UV exposure (Parkin et al., 2011). Exposure to UV
radiation correlates not only with the risk for developing melanoma (Armstrong &
Kricker, 2001) but also with mortality rates (Boniol et al., 2005). The UV spectrum
is divided into three wavelengths: UVA (320-400 nm), UVB (290-320 nm), and
UVC (200-290 nm). As the wavelengths increase in energy (UVC>UVB>UVA),
they penetrate less deeply into the skin and can cause greater direct cellular
damage when absorbed. Although UVC can cause the greatest degree of cellular
damage, a majority of UVC radiation is absorbed by ozone in the atmosphere and
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is therefore not a major contributor to development of melanoma. The remaining
UV radiation associated with ambient sunlight is approximately 90% UVA and 10%
UVB.
Unlike UVC, both UVA and UVB radiation are associated with the pathogenesis of
melanoma due to distinct yet overlapping mechanisms (Gilchrest et al., 1999).
UVB radiation is directly absorbed by nucleobases in DNA to produce the two
major categories of bipyrimidine dimers: cyclobutadipyridime dimers (CPDs) and
pyrimidine (6-4) pyrimidone photoproducts (6,4 PPs) (Sage, 1993; Dumaz et al.,
1997; Tadokoro et al., 2003; Markovitsi et al., 2009). Both are formed via a
cycloaddition reaction: CPDs between the C5 and C6 double bond of two adjacent
pyrmidines and 6,4 PPs between the C5 and C6 double bond of the 5’-base and
the C4 carbonyl on the 3’-pyrmidine (the Paterno-Buchi reaction) (Cadet et al.,
2012). 6,4 PPs have the potential to further absorb UV radiation around 320 nm to
photoisomerize into a third category of photoproducts: the Dewar isomer (Taylor
and Cohrs, 1987; Matsunaga et al., 1991) (Figure 1.2). UVA radiation can also
promote the formation of CPDs (Freeman et al., 1989), however, the mechanism
is not as well characterized as UVB induced photoproducts. It is hypothesized that
a combination of direct UVA photon absorption by DNA (Sutherland et al., 1981)
in addition to photosensitization (Bosca et al., 2006) may contribute to UVA
induced CPDs (Cadet et al., 2012). Photosensitization results from the excitation
of

endogenous

chromophores,

including

melanin,

and

the

subsequent

redistribution of energy to DNA leading to the formation of CPDs (Bosco et al.
2006; Premi et al. 2015).
5
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UVB absorption by DNA results in the formation of cyclobutadipyrimidine
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dimers (CPDs) and pyrimidine (6,4) pyrimidine photoproducts (6,4 PPs).
6,4 PPs can further isomerize to Dewar valence isomers. UVA can also
cause the formation of CPDs following direct absorption and
photosensitization.
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In addition to promoting the formation of bipyrmidine photoproducts, both UVA and
UVB can cause oxidative damage to DNA (Cadet et al., 2015). UVA radiation is
classically associated with an increase in free radicals and oxidative damage.
Oxidative damage from UVA radiation can result either directly from
photosensitization or indirectly via the generation of reactive oxygen and reactive
nitrogen species due to activation of biological processes. Photosensitization can
lead to the formation of charged radicals that react with oxygen producing
superoxide promoting the oxidative signaling pathways (Cadet et al., 2015).
Oxidation of guanine to 8-oxo-7,8-dihydroguanine is a marker of oxidative damage
following UV radiation (Mouret et al., 2006) (Figure 1.3). UVB radiation is also
capable of generating oxidative photoproducts, however, the mechanism by which
UVB contributes to these photoproducts is still undetermined (Wei et al., 1998;
Pelle et al., 2003).
The formation of photoproducts following UV radiation can result in mutations if the
lesions are not recognized and repaired correctly. CPDs have a greater degree of
mutagenicity and are believed to be the major contributor to the generation of two
of the UV signature mutations (You Y et al., 2001): cytosine à thymine base
substitution and cytosine-cytosine à thymine – thymine tandem base substitution
(Brash et al., 1991). 6,4 PPs are repaired more efficiently than CPDs, and therefore
are only minor contributors to UV induced mutations (Ikehata and Ono, 2011). One
of the mechanisms by which substitution mutations occurs is deamination of a
cytosine to uracil in a CPD followed by translesional DNA synthesis (Tessman et
al., 1992; Barak et al., 1995). Translesional DNA synthesis allows the cell to
7
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UVA can cause formation of 8-oxo-7,8-dihydroguanine following
photosensitization or generation of reactive radical species. Exposure to
UVB can also cause the formation of 8-oxo-7,8-dihydroguanine,
however, the mechanism is less clear.
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bypass a stalled replication fork resulting from helix distorting lesions. DNA
polymerase η is specific for error-free translesionsal DNA synthesis opposite
CPDs (Johnson et al., 1999; Masutani et al., 1999; Masutani et al., 2000). If a
cytosine has been deaminated to a uracil in a CPD, DNA polymerase η will pair
the uracil with an adenine instead of guanine resulting in a mutation. A third UV
signature mutation, a guanine à thymine transversion, occurs following oxidative
damage (Ikehata and Ono, 2011) and the base pairing of 8-oxo-7,8dihydroguanine with adenine rather than cytosine. The presence of UV signature
mutations in genes such as p53 in skin cancer contributed to our understanding of
the importance of UV in the pathogenesis of melanoma (Brash et al., 1991).
1.2.1 Nucleotide Excision Repair
Nucleotide excision repair (NER) is the major genome maintenance pathway by
which cells remove bulky DNA lesions that distort the DNA double helical structure
including the UV induced photoproducts 6,4 PPs and CPDs. The NER pathway
involves the coordinated action of multiple factors that recognize, excise, and
repair damaged nucleotides (Figure 1.4).
There are two categories of NER - global genome NER (GG-NER) and
transcription coupled NER (TC-NER) which differ in their initiation mechanism.
GG-NER scans the entire genome for bulky lesions while TC-NER recognizes
DNA damage in transcribed regions of the genome after RNA polymerase has
stalled allowing for repair of the damaged genome without disruption of
transcription (Mellon et al., 1987; Mu & Sancar, 1997; Sugasawa et al., 1998;
9

Figure 1.4 NER Overview
Nucleotide excision repair (NER) is the major mechanism by which cells
remove bulky DNA lesions such as UV photoproducts. NER is
accomplished through the coordinated action of proteins to (1) recognize
DNA damage, (2) access and unwind the DNA in the region of the lesion,
(3) incise and remove the damage, and (4) repair the gap with a high
degree of fidelity using the undamaged strand as a template. In GG-NER,
XPC and HR23B heterodimerize and scan the genome for helical

10

distortions. In TC-NER, CSA and CSB are recruited to sites where RNA
polymerase II has stalled due to helical distortions. The 3’-5’ and 5’-3’
helicases XPB and XPD respectively unwind approximately 20-30
nucleotides surrounding the DNA lesion creating two unprotected single
strand sequences. Replication protein A and XPA are recruited to
stabilize the open DNA conformation. ERCC1-XPF and XPG remove the
damaged base 5’ and 3’ to the damaged base respectively. Polymerase
δ and ε replace the gap.
Abbreviations: CSA – Cockayne syndrome A; CSB – Cockayne
syndrome B; TFIIH – transcription factor II human; RNAPII – RNA
polymerase II; RPA – replication protein A; XP – xeroderma
pigmentosum complementation group
(Adapted from Wolf Horrell et al., 2015)
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Sugasawa et al., 2001; Fousteri et al., 2006). In GG-NER, xeroderma
pigmentosum complementation (XP) group C and HR23B heterodimerize and
scan the genome for helical distortions (Sugasawa et al., 1998; Sugasawa et al.,
2001). In contrast, TC-NER is mediated by Cockayne syndrome A (CSA) and
Cockayne syndrome B (CSB) proteins. CSA and CSB are recruited to sites where
RNA polymerase II has stalled due to helical distortions (Mellon et al., 1987;
Venema et al., 1991; Donahue et al., 1994; Mu and Sancar, 1997; Kamiuchi et al.,
2002). After damage recognition, transcription factor II human (TFIIH), a
multiprotein complex composed of nine proteins, is recruited. TFIIH contains the
3’-5’ and 5’-3’ helicases XPB and XPD respectively (Gerard et al., 1991). The
helicases unwind approximately 20-30 nucleotides surrounding the DNA lesion
creating two unprotected single strand sequences. Replication protein A (RPA)
and XPA are recruited to stabilize the open DNA conformation (Tapias et al., 2004;
Park and Choi, 2006) followed by the endonucleases excision repair crosscomplementation group 1 (ERCC1)-XPF and XPG which remove the damaged
base (Mu and Sancar, 1997; Houtsmuller et al., 1999). Polymerase δ and ε in
combination with proliferating cell nuclear antigen replace the gap using the
undamaged complementary strand for fidelity (Shivji et al., 1995; Cleaver, 2005;
Shah and He, 2015).
The importance of DNA repair in preventing melanoma is evident in individuals
diagnosed with xeroderma pigmentosum (XP) (Li et al., 2006; Paszkowska-Szczur
et al., 2013) who have defective NER due to mutations in one of 8 factors
associated with NER (Cleaver, 1968). These individuals are highly sensitive to UV
12

radiation and experience UV induced skin deformities early in life including
epidermal thinning, telangiectasias, and altered pigmentation. In addition, they
have an increased prevalence of skin malignancies (Eugene and Joshi, 2006) with
a large number of UV induced mutations in oncogenes and tumor suppressors
(D’Errico et al., 2000).

Individuals diagnosed with XP have over 1000 fold

increased risk of development of skin cancer and are often diagnosed with
melanoma in the second decade (on average over 40 years before the general
public) (Bradford et al. 2011).
1.3 Pigmentation
One of the major innate defense mechanisms to protect against UV induced DNA
damage is a high degree of skin pigmentation. Pigment is synthesized by
melanocytes and transferred to keratinocytes in the epidermis where it
accumulates. There are two major types of pigment present in the skin: eumelanin
and pheomelanin. Eumelanin is a dark insoluble polymer that absorbs UV light
(Kaidbey et al., 1979; Scherer and Kumar, 2010) and oxidants (Hoogduijn et al.,
2004), protecting DNA from their damaging effects. In contrast, pheomelanin is a
soluble sulfated red/yellow polymer containing cysteine, which is much less
efficient at blocking penetration of UV radiation and can promote UV-induced
cellular damage by contributing to free radical and oxidative injury (Thody et al.,
1991; Mitra et al., 2012). The degree of skin pigmentation depends on the type
and amount of melanin produced in addition to its cellular distribution rather than
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number of melanocytes present in the skin (Rees, 2003; Dessinioti et al., 2011;
D'Orazio et al., 2013).
Synthesis of both eumelanin and pheomelanin begins with the conversion of
tyrosine to L-3,4-dihydroxyphenylalanine (DOPA) and then to DOPAquinone via
the enzyme tyrosinase (Riley, 1997) (Figure 1.5). Incorporation of a cysteine into
a DOPAquinone molecule eventually leads to the production of pheomelanin rather
than eumelanin. Additional enzymes are required for the synthesis of melanin
including dopachrome tautomerase and dihydroxyindole-2-carboxylic acid
(DHICA) oxidase. Control of the ratio of pheomelanin to eumelanin in a cell is
determined by multiple factors including the cellular pH and levels of the tyrosinase
enzyme (Ancans et al., 2001; Mitra et al., 2012). Higher levels of tyrosinase and
neutral pH favor eumelanin production and darker pigmentation (Burchill et al.,
1986; Ancans et al., 2001). In addition, the melanocortin 1 receptor is the major
genetic factor promoting the synthesis of eumelanin and increasing the ration of
eumelanin:pheomelanin (further discussed below).
Melanoma risk associated with skin pigmentation can be assessed via the
Fitzpatrick skin phototype. The Fitzpatrick score determines an individual’s UV
susceptibility based on basal pigment levels, tendency to burn, and ability to tan
(Fitzpatrick, 1975). Individuals with a lower Fitzpatrick score have fair skin (less
pigment), red or blonde hair, burn easily, and are unable to tan while individuals
with a higher Fitzpatrick score have a darker complexion, do not burn, and tan
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Figure 1.5 Eumelanin and Pheomelanin Synthesis
Eumelanin and pheomelanin are derived from progressive cyclization
and oxidation of the amino acid tyrosine. Tyrosinase catalyzes the
hydroxylation of tyrosine to DOPA and then the oxidation of DOPA to
DOPAquinone. At the level of DOPAquinone, if cAMP levels are
elevated, DOPAquinone undergoes spontaneously cyclization to
leuocDOPAchrome and then to DOPAchrome. DOPAchrome can be
15

leuocDOPAchrome and then to DOPAchrome. DOPAchrome can be
spontaneously converted to either dihydroxyindole (DHI) or converted to
dihydroxyindole-2-carboxylic acid (DHICA) via dopachrome tautomerase
(DCT). DHICA oxidase catalyses the conversion of DHI to indole-5,6quinone and the conversion of DHICA to indole-5,6-hydroquinone-2carboxylic acid. Both indole-5,6-quinone and indole-5,6-hydroquinone-2carboxylic acid are then converted to eumelanin. If cAMP levels are low,
a cysteine in incorporated with DOPAquinone to form cysteinylDOPA.
CysteinylDOPA is oxidized and polymerized to pheomelanin.
Abbreviations: DCT – dopachrome tautomerase; DHI – dihydroxyindole;
DHICA

–

dihydroxyindole-2-carboxylic

acid;

DOPA

dihydroxyphenylalanine; MC1R – melanocortin 1 receptor
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–

L-3,4-

easily. The lower the Fitzpatrick score, the more susceptible an individual is to UV
induced damage and melanoma (Gandini et al., 2005).
1.4 Melanocortin 1 Receptor
One of the major genetic factors associated with protection against UV induced
damage and melanomagenesis is the melanocortin 1 receptor (MC1R). The
human MC1R is 317 amino acids (Garcia-Borron et al., 2005) and was originally
identified and cloned by two independent groups in 1992 (Chhajlani and Wikberg,
1992; Mountjoy et al., 1992). MC1R is a Gs protein coupled receptor located on
the melanocyte plasma membrane whose activation promotes multiple UV
protective pathways including increased melanin synthesis (Suzuki et al., 1997)
and resistance to UV injury through enhanced antioxidant defenses and
acceleration of nucleotide excision repair (Kadekaro et al., 2012; Jarrett et al.,
2014). Following activation with agonistic ligands the Gαs protein dissociates from
MC1R and stimulates adenylyl cyclase activity which cleaves ATP to generate
cAMP. cAMP functions as a second messenger and activates effector proteins
such as the cAMP-dependent protein kinase A (PKA) (Neves et al., 2002; Dorsam
& Gutkind, 2007) which promote the UV protective pathways (Figure 1.6).
1.4.1 MC1R and Pigmentation
As stated above, MC1R is one of the major proteins controlling the switch between
the production of eumelanin and pheomelanin, and is therefore a major control of
pigment production. MC1R has low levels of constitutive ligand independent

17

Figure 1.6 MC1R is a Gs Protein Coupled Receptor
Binding of the melanocortin 1 receptor (MC1R) by its positive agonist α
melanocyte stimulating hormone (αMSH) activates the Gs protein bound
to the receptor by exchanging the GDP for GTP. The Gα subunit
dissociates from the Gβ and Gγ subunits and activates adenylyl cyclase.
Adenylyl cyclase catalyzes the conversion of ATP to cAMP which
functions as a second messenger and promotes the UV protective
pathways.
18

Abbreviations: αMSH - α melanocyte stimulating hormone; MC1R –
melanocortin 1 receptor; UV – ultraviolet
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activity that contributes to basal pigmentation levels (Bennett & Lamoreux, 2003),
and the ability to be activated by endogenous ligands to promote further eumelanin
accumulation.
The importance of MC1R in producing pigment is evident in murine models with
altered MC1R signaling. Mice with the recessive yellow mutation (mutation of the
MC1R gene extension) produce a nonfunctional MC1R and exhibit a blonde
pheomelanotic coat color rather the darkly pigmented coat traditionally found on
the C57/BL6 background (Searle, 1968; Robbins et al., 1993). Conversely, an
increase in MC1R activity found in either the sombre (constitutive active receptor)
or tobacco (hyperactive receptor) mutation is associated with an increase in
eumelanin synthesis and a darker coat color (Robbins et al., 1993). Individuals
with non-functional MC1R proteins also have deficient eumelanin production and
have low levels of basal pigmentation with some variants associated with fair skin
and reddish hair color (discussed further below) (Valverde et al., 1995).
The ability of the skin to respond to UV radiation by increasing eumelanin
production, the adaptive pigmentation pathway, is a major innate protective
mechanism by which the skin prevents further damage from ultraviolet radiation
and is dependent upon MC1R signaling (Figure 1.7). UV radiation causes DNA
damage to keratinocytes in the epidermis of the skin and the subsequent increased
expression of the POMC gene in a p53 dependent manner (Cui et al., 2007).
Cleavage of the proopiomelanocortin (POMC) protein by proconvertase 1 and 2
results in the generation of the MC1R positive agonist α melanocyte stimulating
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Figure 1.7 MC1R Dependent Eumelanin Synthesis
Binding of MC1R by its positive agonist α melanocyte stimulating
hormone (αMSH) leads to activation of adenylyl cyclase and the
21

generation of cAMP. cAMP activates protein kinase A (PKA) which
phosphorylates the cAMP responsive binding element (CREB) at
Ser133. CREB translocates to the nucleus and induces the transcription
of

micropathalmia-associated

transcription

factor

(MITF).

MITF

subsequently functions as a transcription factor and induces the
transcription of multiple genes involved in eumelanin synthesis including
tyrosinase and dopachrome tautomerase.
Abbreviations: αMSH - α melanocyte stimulating hormone; CREB –
cAMP responsive binding element; DCT – dopachrome tautomerase;
MC1R – melanocortin 1 receptor; MITF – micropathalmia-associated
transcription

factor;

PKA

–

protein

proopiomelanocortin; TYR - tyrosinase
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kinase

A;

POMC

–

hormone (αMSH) (Benjannet et al., 1991). Binding of αMSH to MC1R leads to the
activation of adenylyl cyclase and promotes the generation of cAMP (Kadekaro et
al., 2003; Millington, 2006). cAMP accumulation promotes the activation of PKA
leading to the phosphorylation of the cAMP responsive binding element (CREB).
CREB functions as a transcription factor increasing the expression of
microphthalmia-associated transcription factor (MITF). MITF is a master
transcription factor and leads to the increased expression of multiple enzymes
involved in the synthesis of eumelanin including tyrosinase (Yasumoto et al., 1994;
Bertolotto et al., 1996; Levy et al., 2006; Scherer and Kumar, 2010; Bertolotto et
al., 2011).
1.4.2 MC1R and NER
Individuals with defective MC1R signaling are prone to UV induced skin cancer not
only because they have decreased pigmentation but also because they have a
blunted DNA repair response. We and others have reported that activation of
MC1R and the subsequent cAMP signaling cascade are major regulators of NER
kinetics and efficiency (Kadekaro et al., 2005; Smith et al., 2008; Jagirdar et al.,
2013; Jarrett et al., 2014). cAMP signaling directly impacts how long UV
photodamage persists in melanocytes (Hauser et al., 2006; Abdel-Malek et al.,
2009), and repair of photodamage in the skin of mice with humanized skin due to
expression of the K14-Scf transgene is more robust either with a functional MC1R
protein or when pharmacologic agents that induce cAMP signaling are topically
applied to the skin (Jarrett et al., 2014).
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Figure 1.8 MC1R Signaling and Melanocyte Genome Integrity
MC1R

signaling

promotes

genomic

stability

through

multiple

mechanisms. MC1R activation induces translocation of nuclear receptor
subfamily 4 group A member 2 (NR4A2) to the nucleus in a p38 and poly
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ADP ribose polymerase (PARP) with XPC and XPE at sites of UV
induced DNA damage. MC1R activation also leads to elevated levels of
XPC and γH2AX promoting the formation of DNA repair complexes.
Levels of γH2AX are regulated by Wip1 downstream of ATR and DNAPK mediated phosphorylation of p53 at Ser15. In addition, PKA activation
promotes the phosphorylation of ataxia telangiectasia mutated and Rad3
related (ATR) at Ser435. pSer435-ATR complexes with XPA in the
nucleus. Following phosphorylation of XPA, the complex translocates to
sites of UV induced DNA damage to accelerate and enhance nucleotide
excision repair.
Abbreviations: ATR – ataxia telangiectasia mutated and Rad3 related;
DNA-PK – DNA protein kinase; MC1R – melanocortin 1 receptor; NR4A2
– nuclear receptor subfamily 4 group A member 2; PARP – poly ADP
ribose polymerase; PKA – protein kinase A; Wip1 – wild-type p53
induced

phosphatase

1;

XP

complementation group
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–

xeroderma

pigmentosum

Although it has been known for a decade that MC1R signaling accelerates NER
kinetics (Abdel-Malek et al., 2006), the molecular mechanisms by which the
phenomenon occurs have only recently begun to be elucidated and appear to be
complex (Figure 1.8). Acceleration of repair of photo damage has been shown to
be dependent upon both the nuclear receptor subfamily 4 group A member 2
(NR4A2) and ataxia telangiectasia mutated and Rad3 related (ATR) signaling
pathways (Smith et al., 2008; Jagirdar et al., 2013; Jarrett et al., 2014). MC1R
signaling leads to the induction of NR4A2 which translocates to sites of
photodamage in a p38 and poly ADP ribose polymerase (PARP) dependent
manner. The NR4A2/PARP complex colocalizes with the DNA damage proteins
XPC and XPE at sites of DNA damage. Data suggests that NR4A2 may play a role
in promoting chromatin relaxation to promote DNA repair (Smith et al., 2008;
Jagirdar et al., 2013).
Recently, we reported that enhancement of NER by cAMP is dependent upon a
post-translational modification of ATR. Stimulation of MC1R by melanocortins or
pharmacologic cAMP induction causes PKA to phosphorylate ATR at Ser435.
Phosphorylated ATR forms a complex with XPA and recruits XPA to sites of
photodamage enhancing repair and preventing mutagenesis (Jarrett et al., 2014).
Activation of MC1R has also been shown to facilitate repair via an increase in DNA
damage response proteins. Treatment with αMSH leads to an increase in XPC and
γH2AX levels promoting formation of DNA repair complexes in primary human
melanocytes (Swope et al., 2014). There is also a concomitant increase in DNA
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repair gene expression dependent upon MC1R signaling (Kadekaro et al., 2010;
Strub et al., 2011). In addition, MC1R also promotes the return to homeostasis via
p53 signaling. MC1R activation promotes the phosphorylation of p53 at Ser15 in
an ATR and DNA-PK dependent fashion leading to activation of wild-type p53
induced phosphatase 1 (Wip1) and degradation of γH2AX (Kadekaro et al., 2012;
Swope et al., 2014).
1.4.3 Hormonal Regulation of MC1R
MC1R signaling is complex and dynamic and is heavily influenced by receptor
interactions with its ligands: the positive agonist melanocortins, the negative
agonist agouti signaling protein (ASIP), or the neutral antagonist β-defensin 3
(βD3) (Figure 1.9). All three ligands function as competitive inhibitors of each other
as binding of any one ligand to MC1R is mutually exclusive (Ollmann et al., 1998;
Swope et al., 2012; Nix et al., 2013).
There are four endogenous melanocortins: αMSH, βMSH, γMSH, and
adrenocorticotropic hormone (ACTH) which are derived as cleavage products from
the proopiomelanocortin (POMC) protein (Wintzen & Gilchrest, 1996) (Figure
1.10). A byproduct of POMC cleavage is the generation of β-endorphin which is
active at opiate receptors in the skin (Wintzen & Gilchrest, 1996). The UVdependent β-endorphin production and the resultant opiate “high” is believed to
contribute to UV-seeking behavior (Fell et al., 2014). The two major melanocortins
in the skin are αMSH and ACTH (Abdel-Malek et al., 2000). Binding of αMSH or
ACTH to MC1R results in an increase in cAMP levels and the promotion of the
27
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Figure 1.9 MC1R Ligands
Three of the main ligands for MC1R are α melanocyte stimulating
hormone (αMSH), β-defensin 3 (βD3), and agouti signaling protein
(ASIP). The melanocortin αMSH functions as a positive agonist, and
binding of αMSH to MC1R results in activation of adenylyl cyclase (AC)
and an increase in cAMP signaling. ASIP functions as an inverse agonist,
and binding of ASIP to MC1R decreases adenylyl cyclase activity. βD3
is a neutral antagonist, and binding of βD3 to MC1R does not affect
adenylyl cyclase activity or cAMP levels. All three ligands function as
competitive inhibitors, and binding of one ligand precludes binding of the
others.
Abbreviations: AC – adenylyl cyclase; MC1R – melanocortin 1 receptor
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Figure 1.10 Melanocortin Synthesis via Proopiomelanocortin (POMC)
Processing
Melanocortins are derived from the proopiomelanocortin (POMC)
precursor peptide. It is cleaved into functional protein fragments via a pair
of serine proteases proprotein convertase (PC) 1 and 2. PC1 cleaves
POMC into four subunits including an N-terminal region, a junctional
protein (JP), adrenocorticotropic hormone (ACTH), and β lipotropin
(βLPH). The N-terminal is cleaved by PC2 to produce γ melanocyte
stimulating hormone (MSH). ACTH is cleaved by PC2 to generate αMSH
and the corticotropin like intermediate peptide (CLIP). βLPH is cleaved
by PC2 generate γLPH and β endorphin. γLPH is subsequently cleaved
by PC2 to generate βMSH.
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Abbreviations:

ACTH

–

adrenocorticotropic

hormone;

CLIP

–

corticotropin like intermediate peptide; JP – junctional protein; βLPH - β
lipotropin; MSH – melanocyte stimulating hormone; PC – proconvertase
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MC1R dependent UV protective pathways: accumulation of eumelanin and
acceleration of NER. ASIP functions to decrease MC1R signaling via two
mechanisms. First, it acts as a competitive MC1R inhibitor preventing αMSH from
binding to MC1R inhibiting melanocortin induced MC1R activation (Blanchard et
al., 1995). In addition, ASIP also functions as an inverse agonist and reduces basal
MC1R signaling (Lu et al., 1994; Wilson et al., 1995). Binding of ASIP to MC1R
prevents αMSH induced tyrosinase, tyrosine related proteins 1 and 2, and MITF
expression suppressing melanogenesis (Aberdam et al., 1998), and in addition,
decreases basal tyrosinase activity and tyrosinase and tyrosinase related protein
1, 2, and 3 levels (Sakai et al., 1997; Abdel-Malek et al., 2001). ASIP signaling
also affects NER, and treatment with ASIP decreases both basal NER kinetics in
a dose dependent manner (Jarrett et al., 2015) and prevents the acceleration of
NER downstream of αMSH (Jarrett et al., 2014; Jarrett et al., 2015).
βD3 belongs to a group of antimicrobial peptides that link the innate and adaptive
immune responses and was only shown to interact with MC1R within the last
decade (Candille et al. 2007). Although binding of βD3 to MC1R does not affect
basal cAMP levels (Swope et al., 2012; Nix et al., 2013), it competes with both
ASIP and αMSH preventing them from binding and altering MC1R signaling. βD3
prevents αMSH induction of the pigment pathway (Swope et al., 2012) and inhibits
the phosphorylation of ATR by PKA at Ser435 and the subsequent enhancement
of DNA repair downstream of αMSH (Jarrett et al., 2015).
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1.5. Targeting the Melanocortin-MC1R Signaling Axis
MC1R is a highly polymorphic protein with over 100 variants reported in the human
population (Seabrook et al., 2005; Gerstenblith et al., 2007; Perez Oliva et al.,
2009) . Five specific variants, D84E, R142H, R151C, R160W, and D294H, result
in MC1R loss-of-function and are associated with a decrease in pigment
production and the “red hair color” (RHC) phenotype (Valverde et al., 1995; Box et
al., 1997; Flanagan et al., 2001). Individuals with RHC variant mutations have an
increased sensitivity to UV exposure and elevated melanoma risk because they
are unable to prevent and repair UV damage. They have decreased eumelanin
synthesis and therefore have low basal pigmentation and an inability to tan. These
individuals burn easily and accumulate a greater degree of UV induced damage.
They also cannot accelerate their DNA repair, therefore, the damage they sustain
is not repaired as quickly and is more likely to result in mutation (Bohm et al., 2005;
Hauser et al., 2006).
Pharmacologic enhancement of the MC1R pathway represents a major
opportunity to augment the innate UV protective pathways to prevent development
of skin cancer. MC1R signaling can be manipulated either via melanocortin
analogs (Abdel-Malek et al., 2006) to directly stimulate MC1R or by bypassing the
receptor and increasing cAMP levels by activating adenylyl cyclase (i.e. forskolin)
(D’Orazio et al., 2006) or inhibiting cAMP degradation via a phosphodiesterase
inhibitor (i.e. rolipram) (Khaled et al., 2010). Although melanocortin analogs do
require a functional MC1R, and therefore, could not be utilized in the RHC
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population, they offer a melanocyte specific targeted approach. Topical application
of forskolin or rolipram, however, would result in an increase in cAMP signaling
throughout the skin as both forskolin and rolipram bypasses MC1R and directly
increase cAMP levels.
Although the activation of the UV protective pathways downstream of MC1R is
beneficial, unregulated enhancement of MC1R signaling has the potential for
dangerous consequences. MC1R activation, in addition to promoting the UV
protective signaling pathways, also promotes melanocyte proliferation (Suzuki et
al., 1996; Kadekaro et al., 2003) (Figure 1.11). Physiologically, the interaction of
the positive and inhibitory ligands prevents the receptor from constant activation.
Pharmacologic enhancement of MC1R signaling that bypasses the receptor,
however, cannot be innately regulated. Consequently, augmentation of the MC1R
signaling axis has the risk for uncontrolled melanocyte proliferation and
melanomagenesis. In theory, in order for this approach to be safe in humans, the
risk for melanocyte proliferation must be negligible, therefore, it is important to
better understand the signaling mechanism by which MC1R promotes melanocyte
proliferation.
1.6 Overall Scope of This Dissertation
The overall goal of this dissertation is to further elucidate the complexities of MC1R
signaling, and specifically to assess the interdependence of the pigmentation,
NER, and proliferation pathways to determine whether any one pathway could be
selectively augmented or inhibited in a translationally relevant manner. Both the
33

Figure 1.11 Pharmacologic Manipulation of MC1R
MC1R signaling can be pharmacologically manipulated either directly
via α melanocyte stimulating hormone (αMSH) analogs or via forskolin
which bypasses the receptor and directly activates adenylyl cyclase.
αMSH analogs can only be used for individuals with a functional MC1R
protein while activation of adenylyl cyclase can be used for individuals
with a loss-of-function MC1R protein. cAMP stimulus results in activation
of three pathways: 1) induction of eumelanin synthesis, 2) acceleration
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of NER, and 3) induction of melanocyte proliferation
Abbreviations: αMSH - α melanocyte stimulating hormone; AC – adenylyl
cyclase; MC1R – melanocortin 1 receptor
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induction of eumelanin synthesis and the acceleration of NER are well
characterized and dependent upon PKA signaling downstream of MC1R and
cAMP. MC1R induced melanocyte proliferation is less well understood. In order to
determine whether the three pathways can be independently manipulated
pathways, the interdependence between the pathways must first be determined.
The specific aims of this dissertation were: 1) to determine the role of UV in the
regulation of the expression of the MC1R neutral antagonist βD3, 2) to directly test
the interdependence and cross talk between the two UV protective pathways, and
3) to determine the mechanism by which MC1R promotes melanocyte proliferation
and to determine whether MC1R proliferation can be selectively inhibited while
maintaining eumelanin synthesis and the acceleration of NER downstream of
MC1R. The overall hypothesis of this dissertation is that the three pathways
downstream of MC1R can be independently manipulated to protect against UV
induced damage.
Chapter 2 investigates the regulation of the MC1R neutral antagonist βD3 gene.
UV naïve human neonatal foreskins were utilized to assess the role of
inflammation and UVB induced DNA damage on the induction of βD3 mRNA
expression.
Chapter 3 investigates the interaction and cross talk between the two UV protective
pathways downstream of MC1R: the induction of eumelanin synthesis and the
acceleration of NER. Primary human melanocytes and transformed human
melanoma cell lines were utilized to assess the role of the MITF transcription factor
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in the acceleration of DNA repair and the role of ATR in the activation of the
adaptive pigmentation pathway.
Chapter 4 investigates the role of mTOR on MC1R induced melanocyte
proliferation and the interaction between the proliferation pathway and the UV
protective pathways downstream of MC1R (the induction of eumelanin synthesis
and acceleration of NER). A transformed melanoma cell line was utilized to
determine the signaling pathway responsible for MC1R induced proliferation. In
addition, a transformed melanoma cell line and an MC1R-null murine mouse model
were used to assess the potential to selectively manipulate and inhibit MC1R
induced proliferation while maintaining the UV protective pathways in vitro and in
vivo.
In summary, primary human melanocyte and transformed human melanoma cell
lines in addition to an MC1R null-murine mouse model and human neonatal
foreskin explants were utilized to further elucidate the regulation of MC1R ligands
and signaling pathways.

Copyright © Erin Marissa Wolf Horrell 2016
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________________________________________________________________
Chapter 2: UV-Independent Induction of Beta Defensing 3 in Neonatal
Human Skin Explants
________________________________________________________________
Adapted from Wolf Horrell E. and D’Orazio J. (2015). UV-Independent
Induction of Beta Defensing 3 in Neonatal Human Skin Explants.
F1000Research 3, 288.
2.1 Introduction
The melanocortin 1 receptor (MC1R) is a Gs protein coupled receptor expressed
on melanocytes that regulates several key aspects of cutaneous UV responses.
When bound by agonistic ligands, most notably α melanocyte stimulating hormone
(αMSH) (Suzuki et al., 1996), MC1R initiates a cascade of UV-protective events
mediated by activation of adenylyl cyclase and generation of cAMP that result in
melanin production and enhanced genome stability via enhancement of DNA
repair (Kadekaro et al., 2005). In addition to αMSH, MC1R signaling is regulated
by other soluble ligands, most notably agouti signaling protein (ASIP) which
antagonizes

MC1R

signaling,

decreases

cAMP

levels,

and

diminishes

downstream melanocyte responses such as pigment induction (Millar et al., 1995;
Suzuki et al., 1997). Recently, it has become clear that β-defensin 3 (βD3), known
for its role in innate antimicrobial immunity, binds and influences MC1R signaling
as a neutral MC1R agonist that blunts αMSH-mediated MC1R activation as well
as ASIP-mediated MC1R antagonism (Candille et al., 2007; Kaelin et al., 2008;
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Beaumont et al., 2012; Swope et al., 2012). Thus, βD3 may be an important
regulator of MC1R-dependent melanocyte responses in the skin.
Because UV radiation is a major causative agent for melanoma and other skin
cancers and because MC1R signaling mediates critical UV-protective responses
such as melanization of the skin and melanocytic resistance to UV mutagenesis,
it is important to understand how UV affects expression of MC1R ligands in the
skin. αMSH levels increase in response to UV exposure of the skin. Cui and
coworkers

reported

that

UV

promoted

transcriptional

increases

in

proopiomelanocortin (POMC), the protein precursor for αMSH, in a cell damage
and p53-dependent manner in epidermal keratinocytes (Cui et al., 2007),
supporting the hypothesis that melanocytic MC1R responses are modified by
intracutaneous UV-regulated mechanisms. Similarly, recent studies reported that
UVB radiation caused an increase βD3 mRNA and protein levels both in vivo and
in vitro (Glaser et al., 2009), either in a cell-autonomous, damage-dependent
manner or in response to inflammatory mediators such as interleukin-1 (IL-1β) and
tumor necrosis factor-α (TNFα) known to promote its induction (Jia et al., 2001;
Harder et al., 2001). In an effort to understand the mechanisms of how βD3
production may be influenced by UV radiation, we determined its expression in
freshly isolated human skin explants. Here we report that βD3 expression
increases in a UV-independent manner in neonatal human skin explants in
response to processing and culturing of tissues ex vivo.
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2.2 Methods
2.2.1 Neonatal Foreskin Explants
Freshly-isolated, de-identified neonatal foreskins were collected from normal
newborn infants undergoing planned circumcision from the University of Kentucky
Birthing Center under an IRB-exempted protocol. Foreskins were collected only
from patients who were consented prior to delivery. Samples were placed into 30
mL of Roswell Park Memorial Institute (RPMI) media (Life Technologies) and
stored at room temperature for a maximum of four hours before processing.
Samples were rinsed in phosphate buffered saline (PBS) + 1% penicillin
streptomycin (Life Technologies), and dermal fat was manually removed by
forceps to the point that explants would lie completely flat. Explants were placed
in 3 cm cell culture dishes and floated dermal side down on 3 mL of RPMI media
with 10% fetal bovine serum for 16–18 hours at 4°C until use. Prior to UV
treatment, explants were divided into roughly equal-sized pieces. Following UV
treatment, explants were maintained in 3 mL of RPMI + 10% fetal bovine serum +
1% penicillin streptomycin in a humidified incubator at 37°C with 5% CO2. The
media was changed every 48 hours.
2.2.2 Skin Color Measurement
Skin reflective colorimetry was assessed with a CR-400 Colorimeter (Minolta
Corporation) calibrated against a white background. Degree of melanization
(darkness) was quantified as the colorimetric measurement on the *L axis (white-
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black axis) of the CIE standard color axis (Wagner et al., 2002). The degree of
pigmentation was determined by three independent measurements for each
sample.
2.2.3 Ex Vivo UV Exposure
Skin explants were exposed (epidermal side up) to an overhead double bank of
UVB lamps (UV Products) to receive 0.5 kJ/m2 UVB, a dose similar to that reported
previously with respect to cutaneous βD3 induction in vivo (Glaser et al., 2009;
Hong et al., 2008). UV emittance was measured with a Model IL1400A handheld
flash measurement photometer (International Light) equipped with separate UVB
(measuring wavelengths from 265–332 nm; peak response at 290 nm) and UVA
(measuring wavelengths from 315–390 nm; peak response at 355 nm) filters
corresponding to International Light product numbers TD# 26532 and TD# 27108
respectively. Spectral output of the lamps was determined to be roughly 75% UVB
and 25% UVA. Following exposure to UV radiation, samples were flash frozen at
the indicated times for further processing.
2.2.4 Hematoxylin and Eosin Tissue Staining
Four neonatal skin explants were divided into two biopsies. One biopsy was
untreated and harvested at time 0. The other was exposed to 0.5 kJ/m2 UVB
radiation and harvested at 24 hours. The biopsies were placed in 4%
paraformaldehyde for 48 hours to fix the sample and subsequently placed in 70%
ethanol. Samples were embedded in paraffin. Samples were processed, sectioned
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at a thickness of 4 µm and stained for hematoxylin and eosin (Dako) by the
University of Kentucky Markey Cancer Center Biospecimen and Tissue
Procurement Shared Resource Facility.
2.2.5 mRNA Isolation
Total RNA was harvested from skin using TRIzol (Life Technologies). 25 mg of
sample were placed in 500 µL of TRIzol and ground to a fine consistency using a
dounce homogenizer. Homogenized sample was incubated for 5 minutes at room
temperature. 100 µL of chloroform were added to each sample, and each sample
was shaken vigorously for 15 seconds. Sample was incubated for 2–3 minutes at
room temperature. Sample was centrifuged at 12,000 × g for 15 minutes at 4°C.
RNA was isolated in the aqueous phase. RNA was precipitated with 250 µL of
isopropanol. Sample was incubated at room temperature for 10 minutes and then
centrifuged at 12,000 × g for 10 minutes at 4°C. Supernatant was removed. The
RNA pellet was washed with 500 µL of ethanol and centrifuged at 7,500 × g for 5
minutes at 4°C. Supernatant was removed and the RNA pellet was dissolved in 50
µL RNase DNase free distilled water. RNA concentration was determined utilizing
a Nanovue nanodrop (GE Healthcare).
2.2.6 Reverse Transcriptase Polymerase Chain Reaction (RTPCR)
1 µg of RNA was reverse transcribed to cDNA utilizing random hexamers and MMLV reverse transcriptase (Promega) in a Mastercycler epgradient thermocycler
(Eppendorf International). cDNA was diluted 1:10 in RNase DNase free distilled
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water for use in quantitative real time polymerase chain reaction.
2.2.7 Quantitative Real Time Polymerase Chain Reaction (qRTPCR)
Quantitative real time polymerase chain reaction (qRTPCR) analysis was
performed using an Applied Biosystems 7500 Real Time PCR System (Life
Technologies) (10 ng cDNA/reaction) utilizing TATA-binding protein (TBP) as a
reference gene. Primer sets for TBP were 5´-CAGCGTGACTGTGAGTTGCT-3’
(left) and 5´-TGGTTCATGGGGAAAAACAT-3’ (right), for βD3 were 5´TAGGGAGCTCTGCCTTACCA-3’ (left) and 5´-CACGCTGAGACTGGATGAAA-3’
(right), for TNFα were 5´-TCCTTCAGACACCCTCAACC-3’ (left) and 5´AGGCCCCAGTTTGAATTCTT-3’

(right),

and

for

tyrosinase

were

5´-

TACGGCGTAATCCTGGAAAC-3’ (left) and 5´-ATTGTGCATGCTGCTTTGAG-3’
(right) (Integrated DNA Technologies).
2.2.8 Statistics and Data Analysis
Correlation and linear regression analysis were performed using GraphPad Prism
5.0 (GraphPad Software). Data were considered statistically significant if p values
were less than 0.05 from multiple independent experiments.
2.3 Results
2.3.1 βD3 Induction is Independent of Skin Pigmentation
To understand the effects of UV radiation on βD3 expression in human skin,
freshly-isolated foreskins were exposed to 0.5 kJ/m2 UVB. Fourteen de-identified
43

samples were obtained from normal healthy male infants undergoing elective
circumcision before discharge from the neonatal nursery. Skin pigmentation was
measured for each sample three independent times by reflective colorimetry in
order to estimate melanin content of the epidermis. The skin samples exhibited a
range of melanization as determined by the *L score which quantifies color on a
black-white color axis (a lower *L score is indicative of a blacker/darker color and
correlates with epidermal eumelanin content (D’Orazio et al., 2006)). The majority
of the samples were derived from light-skinned infants, however at least 3 samples
were darker in color (Figure 2.1).
Skin explants were exposed to 0.5 kJ/m2 UVB, and biopsies were taken from the
explants at 6, 12, 24, 48, and 72 hours following UV exposure. βD3 mRNA
expression was measured by qRTPCR at 6, 12, 24, 48 and 72 hours after radiation,
normalized to TBP, and compared to an unirradiated control taken at time 0. Due
to the small size of the skin explants (roughly 1 cm2), it was not possible to have a
time-matched mock-irradiated control at each time point, therefore values were
normalized to unirradiated controls from each skin sample. We noted extensive
variability in both the timing and magnitude of βD3 induction across individuals
(Figure 2.2 A). Normalized βD3 fold induction ranged from 1.3-fold to 44.8-fold,
and peak induction ranged from 6–72 hours depending on the sample (Figure 2.2
B). We tested whether the amount of βD3 expression correlated with skin
pigmentation, hypothesizing that more melanin in the skin might inhibit UV
penetration into the skin and therefore blunt UV effects on βD3 expression. In fact,
βD3 expression did not appear to be influenced by pigment phenotype, as
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Figure 2.1 Degree of Skin Pigmentation from Each Donor
Skin color determination is shown for each sample. *L Score is measured
by reflective colorimetry and represents color of the skin on a black-white
axis. Lower *L score is indicative of a more darkly pigmented phenotype.
Data represent the average *L score ± SEM for three measurements per
skin sample.
(Adapted from Wolf Horrell and D’Orazio, 2015)
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Figure 2.2 βD3 mRNA Induction Varies Between Individuals
A) Fourteen independent human skin explants (Samples A–N) were
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treated ex vivo with 0.5 kJ/m2 UVB radiation. βD3 mRNA expression was
determined at 6, 12, 24, 48, and 72 hours following UV treatment and
compared to untreated matched controls.
B) Time of maximal βD3 expression after UV radiation across samples.
Peak βD3 mRNA expression for human skin explants (n=14) is arranged
by time of maximal induction for each individual donor. qRTPCR was
performed in duplicate for each sample, and results are expressed as
mean fold change over control ± SEM.
(Adapted from Wolf Horrell and D’Orazio, 2015)
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manifested by a positive trend between higher βD3 expression and darker skin
samples (Figure 2.3 A; r2 = 0.057, p = 0.41). Similarly, a negative trend between
skin color and time of peak βD3 expression was observed, although this too did
not reach statistical significance (Figure 2.3 B; r2 = 0.234, p = 0.08).
2.3.2 βD3 Induction in Skin Explants is Independent of UV Exposure
We then considered the possibility that βD3 expression might be affected simply
by time in culture and measured βD3 expression over time in samples exposed to
0 or 0.5 kJ/m2 UVB exposure. Each of five explants were divided into three sections
and sampled either at time 0 (no UV) or at 24 hours following exposure to either 0
or 0.5 kJ/m2 UVB. Similar to prior experiments, βD3 expression was measured by
qRTPCR and normalized to TBP, however values could also be compared with
mock-irradiated, time-matched conditions. We observed clear induction of βD3
expression in each of the mock-irradiated samples over time (Figure 2.4 A), and
exposure to 0.5 kJ/m2 UVB did not substantially alter βD3 mRNA expression when
compared to individual mock-irradiated time-matched controls. We assessed
whether the processing of the samples led to sample degradation via
immunohistochemistry. Staining revealed that after 24 hours of ex vivo treatment,
the samples appeared similar to those at time 0 and suggested their viability
(Figure 2.4 B). These data suggest that either tissue removal or the process of
culturing skin explants ex vivo in our culture conditions is sufficient to enhance βD3
expression in whole human neonatal skin and that the addition of 0.5 kJ/m2 UVB
does not impact βD3 expression in this setting.
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Figure 2.3 Relationship Between Donor Skin Color and βD3 Expression
A) *L score versus peak βD3 mRNA induction. qRTPCR was performed
in duplicate for each sample, and data represent mean βD3 induction for
14 human skin explants. There was no correlation between donor *L
score and amplitude of βD3 induction (r2 = 0.057, p = 0.41).
B) *L score versus time of peak βD3 mRNA induction. qRTPCR was
performed in duplicate for each sample, and data represent mean βD3
induction for 14 human skin explants. Although a weak negative trend
existed between donor *L score and time of βD3 induction, the correlation
was not statistically significant (r2 = 0.234, p = 0.08).
(Adapted from Wolf Horrell and D’Orazio, 2015).
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Figure 2.4 UV-independent βD3 Expression in Human Skin Explants
Cultured Ex Vivo
A) UVB independent induction of βD3. Five human neonatal skin
explants (Samples O–S) were treated ex vivo with 0.5 kJ/m2 UVB
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radiation. βD3 mRNA expression of UV-treated samples and unirradiated
time-matched controls were compared to unirradiated time-matched
controls taken at time 0. qRTPCR was performed in duplicate for each
sample, and data represent the mean fold change over the untreated
control taken at the time of UV treatment ± SEM.
B) Histological analysis of neonatal skin samples at time 0 or 24 hours
after UVB irradiation (0.5 kJ/m2; Samples T–W). Tissues were stained
with hematoxylin and eosin to assess tissue degradation.
(Adapted from Wolf Horrell and D’Orazio, 2015)
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2.3.3 βD3 Induction In Skin Explants Correlated with TNFα Levels
Because cytokines, particularly TNFα are known to regulate βD3 expression, we
tested whether TNFα gene expression was induced in the human neonatal skin
samples following UV radiation. TNFα mRNA levels were assessed via qRTPCR
at 6, 12, 24, 48, and 72 hours following UVB radiation, normalized to TBP, and
compared to unirradiated controls. TNFα mRNA levels increased with time after
UV in the majority of samples tested (Figure 2.5 A). Normalized TNFα mRNA
induction ranged from 0–14.3 fold across samples. TNFα and βD3 induction
weakly correlated over time (Figure 2.5 B, r2 = 0.335, p<0.0001) suggesting a
relationship between the two genes. UV-independent TNFα induction was then
assessed in four additional samples. We observed that in three of four samples,
TNFα expression increased in culture without UV (Figure 2.6), suggesting that
tissue processing may increase TNFα levels independently from UV.
We then assessed whether ex vivo culture conditions used in these experiments
affected other genes known to be regulated following UV radiation. Tyrosinase
gene expression was measured in four human neonatal skin samples 24 hours
after mock- or UV-irradiation. UV increased levels of tyrosinase gene expression
in two of the four samples (Figure 2.7), suggesting that these culture conditions
may be appropriate for other genes if properly controlled.
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Figure 2.5 TNFα mRNA Induction in Human Skin Explants Cultured Ex
Vivo
A) TNFα expression over time among 14 distinct donors after UV
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radiation. Fourteen independent neonatal human skin explants (Samples
A–N) were treated ex vivo with 0.5 kJ/m2 UVB radiation. TNFα mRNA
expression was determined at 6, 12, 24, 48, and 72 hours following UV
treatment and compared to matched untreated controls.
B) Correlation of βD3 and TNFα mRNA expression over time. βD3 and
TNFα mRNA expression were compared among fourteen human skin
explants (Samples A–N) at 0, 6, 12, 24, 48, and 72 hours. βD3 and TNFα
mRNA expression correlated over time (r2 = 0.335, p<0.0001). qRTPCR
was performed in duplicate for each sample, and results are expressed
as mean fold change over control ± SEM.
(Adapted from Wolf Horrell and D’Orazio 2015)
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Figure 2.6 UV-independent TNFα Expression in Human Skin Explants
Cultured Ex Vivo
UVB independent induction of TNFα. Four neonatal human skin explants
(Samples O–R) were treated ex vivo with 0.5 kJ/m2 UVB radiation. TNFα
mRNA expression for UV-treated biopsies and unirradiated timematched controls were compared to unirradiated tissue-matched
controls taken at time 0. qRTPCR was performed in duplicate for each
sample, and data represent the mean fold change over the untreated
control taken at the time of UV treatment ± SEM.
(Adapted from Wolf Horrell and D’Orazio, 2015)
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Figure 2.7 Tyrosinase mRNA Expression in Human Skin Explants Cultured
Ex Vivo
Four neonatal human skin explants (Samples O–R) were treated ex vivo
with 0.5 kJ/m2 UVB radiation. Tyrosinase mRNA expression was
determined for UV treated biopsies and unirradiated time-matched
controls and compared to tissue-matched unirradiated controls taken at
time 0. qRTPCR was performed in duplicate for each sample, and data
represent the mean fold change over the untreated control taken at the
time of UV treatment ± SEM.
(Adapted from Wolf Horrell and D’Orazio, 2015).
56

2.4 Conclusions/Discussion
In an effort to develop a model in which to study UV induction of cutaneous βD3,
we measured its expression over time in UV-naïve human skin explants. Although
there was a high degree of variability in the magnitude and kinetics of βD3
induction between samples harvested from different donors, we observed βD3 upregulation in each case. To control for the possibility that tissue processing and/or
ex vivo culture conditions might impact βD3 expression in the explants, we
compared βD3 mRNA levels between mock-irradiated versus UV-treated sections
of skin samples harvested from the same donor. This experiment, which included
samples from five donors, indicated that βD3 expression increased over time
irrespective of UV exposure (at 0.5 kJ/m2), suggesting that βD3 expression is
induced in human skin explants in a UV-independent manner.
βD3 expression has been reported to be up-regulated in wound healing processes
(Kesting et al., 2010), therefore it might be plausible that its increase over time in
skin explants may be related to normal wound physiologic processes activated by
surgical excision of the skin and/or its processing after harvest. The small size of
the skin samples isolated from neonatal circumcision (on average 1–1.5 cm2)
implies that the majority of the tissue in the explant will be in close proximity to at
least one cut surface, raising the possibility of local trauma-induced factors
contributing to βD3 expression in the samples. TNFα is an inflammatory cytokine
known to be upregulated in the wound healing process, and TNFα mRNA was also
induced in the skin samples independently from UV radiation. TNFα induction over
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time correlated with βD3 mRNA induction providing further support that βD3
induction in the skin explants may be related to normal wound healing processes.
Our data do not rule out the possibility that the wounding response following
surgical excision and processing may be sufficiently robust as to prevent further
induction by UV. Tyrosinase mRNA levels, however, were induced following UV
radiation in 50% of the samples suggesting some genes regulated by UV can be
induced in our ex vivo model. Alternatively, it is possible that one or more factors
involved in sustaining the skins in culture (media, temperature, oxygen tension,
pH, etc.) may have promoted βD3 expression in the explants. We do not as yet
understand the mechanism(s) underlying variability of βD3 induction amplitude or
kinetics observed between samples, however it is possible that wounding or
inflammatory responses induced by tissue removal may vary between normal
individuals.
Previous studies have utilized adult human skin explants and reported an induction
of βD3 mRNA following UV radiation in ex vivo culture conditions (Glaser et al.,
2009). It is possible that neonatal skin explants behave differently than adult skin
explants, accounting for the inconsistent results between the two studies. In
general, neonatal immune responses are less mature than those of adults,
perhaps contributing to these observations. In addition, prior UV exposures of
adult-derived skin tissues may not be controlled as are skin explants from UVnaïve neonatal foreskins which may also impact results. We conclude that because
of confounding variables involved in their generation and maintenance, neonatal
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foreskin explants processed via the conditions outlined above may not be an
appropriate model to isolate the effects of UV on βD3 expression in the skin,
however other models may still be appropriate.
2.5 Consent
De-identified neonatal foreskin samples were obtained from the University of
Kentucky’s Chandler Medical Center Newborn Nursery without accompanying
clinical information under an institutionally-reviewed IRB-exempted status.

Copyright © Erin Marissa Wolf Horrell 2016
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________________________________________________________________
Chapter 3: MC1R Enhanced DNA Repair is Independent of MITF but
Pigment Induction Depends on ATR
________________________________________________________________
3.1 Introduction
Loss-of-function polymorphisms in the melanocortin 1 receptor (MC1R) signaling
axis represent a major inherited risk factor for melanoma (Valverde et al., 1995;
Kennedy et al., 2001), which currently affects nearly 1 in 50 people in the United
States and accounts for more than 80% of skin cancer deaths (Surveillance,
Epidemiology, and End Results, February 2016). Ultraviolet (UV) radiation is a
major environmental driver of melanoma, as evidenced by the abundance of UVsignature pyrimidine transitional mutations in many melanomas (Brash et al. 1991;
Hodis et al., 2012; Shain et al., 2015). UV signature mutations result from the
formation of UV photoproducts including pyrimidine 6,4 pyrimidone photoproducts
(6,4 PPs) and cyclobutadipyrimidine dimers (CPDs), which if not repaired in a
timely manner, can result in mutations and promote carcinogenesis (Brash and
Haseltine, 1982).
MC1R is a Gs protein coupled receptor located on the melanocyte cell membrane
that is integral to melanocytic UV responses. Activation of the receptor following
exposure to UV results in the induction of two major protective pathways to blunt
and repair UV damage in melanocytes: 1) increase in eumelanin synthesis
(adaptive pigmentation) (D'Orazio et al., 2006; Cui et al., 2007) and 2) acceleration
60

of nucleotide excision repair (NER), the genome maintenance pathway chiefly
responsible for the removal of UV photoproducts from nuclear DNA (Bohm et al.,
2005; Hauser et al., 2006; Jagirdar et al., 2013; Jarrett et al., 2014; Smith et al.,
2008).
MC1R signaling results in the accumulation of cAMP and activation of protein
kinase A (PKA) (Kadekero et al., 2003; Millington et al., 2006), however how the
downstream responses are regulated is incompletely understood. Induction of
eumelanin synthesis is largely dependent upon PKA mediated phosphorylation of
the cAMP responsive binding element (CREB) transcription factor at Ser133 and
subsequent induction of the microphthalmia-associated transcription factor (Mitf)
gene (Bertolotto et al., 1998; Price et al., 1998). In turn, MITF promotes the
transcription of enzymes responsible for the synthesis of eumelanin including
tyrosinase and dopachrome tautomerase (Levy et al., 2006). Recently, we
reported that MC1R signaling accelerates NER through PKA’s phosphorylation of
the ataxia telangiectasia mutated and Rad3 related (ATR) protein at Ser435.
pSer435-ATR complexes with xeroderma pigmentosum complementation group A
(XPA) thereby recruiting XPA to sites of photodamage enhancing repair and
preventing mutagenesis (Jarrett et al., 2014).
Studies have begun to address the interaction between the two pathways.
Activation of the pigment pathway and the accumulation of eumelanin have been
shown to limit the extent of UV induced DNA damage, however, only MC1R
function and not the presence of pigment affected the kinetics of DNA repair
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(Hauser et al., 2006). MITF is a basic helix-loop-helix protein that functions as a
global transcription factor and has been shown to induce genes associated with
NER including RPA2 and POLE2 among others (Strub et al., 2011). This paper
intends to further assess the cross talk between the pigmentation and repair
pathways and directly test the role of MITF on NER and ATR on pigmentation.
3.2 Methods
3.2.1 Cell Lines and Pharmacologic Treatments
Transformed melanoma SK-MEL-2 (ATCC) cells and primary human melanocytes
(Coriell Institute for Medical Research) were cultured in Roswell Park Memorial
Institute (RMPI) media (Life Technologies) with 10% fetal bovine serum and
Cascade Biologics Medium 254 (Life Technologies) respectively. Forskolin (LC
Laboratories) and VE-821 (Selleckchem) were utilized as indicated. siRNA
targeted to ATR (Dharmacon) and MITF (Dharmacon) were performed according
to the manufacturer’s instructions.
3.2.2 UV Exposure In VItro
Cells were treated with 0.1% ethanol vehicle, 10 µM forskolin, 10 µM VE-821, or a
combination of 10 µM forskolin and 10 µM VE-821 as indicated for 1 hour prior to
UV exposure. UV radiation was measured via a Model IL1400A handheld flash
measurement photometer (International Light) with a UVB filter (assessing
wavelengths between 265-332 nm with a peak response at 290 nm). Media was
removed from the cells, and cells were exposed to a dose of 10 J/m2 UVB.
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3.2.3 Antibodies
Antibodies directed against pSer435-ATR were previously generated against the
peptide CPKRRR(pS)SSLNPS (Amsbio) as previously reported (Jarrett et al.,
2014). Commercially available antibodies included anti-CPD (Kamiya Biomedical),
anti-ATR (Cell Signaling) anti-CREB (Cell Signaling), anti-pSer133-CREB (Cell
Signaling), MITF (Cell Signaling), anti-Chk1 (Cell Signaling), and anti-pSer317Chk1 (Cell Signaling).
3.2.4 pSer435-ATR Detection
pSer435-ATR kinase assays were performed as previously described (Jarrett et
al., 2015) using the biotinylated ATR peptide substrates CPKRRRLSSSLNPS
(Genscript). Cells were plated in a 6 well well plate and treated with 0.1% ethanol
vehicle or 10 µM forskolin for 1 hour prior to harvesting. 100 µM biotinylated ATR
peptide substrate was added to a stepavidin-coated 96 well plate. 20 µg of whole
cell lysate was added to the wells in 40 mM Tris-HCL (pH 7.5), 10 mM MgCl2, 1
mM dithiothreitol (DTT), 100 µg/mL bovine serum albumin, and 10 µM ATP. The
kinase reaction was performed at 30°C with gentile agitation. The reaction was
terminated via the addition of 10 µL of 100 mM EDTA at 1 hour. PKA
phosphorylation was measuring utilizing the anti-pSer435-ATR primary antibody.
The primary antibody was conjugated to a horseradish peroxidase (HRP)conjugated anti-rabbit secondary antibody (Abcam) for 1 hour followed by the
addition of QuantaBLu (Pierce). Fluorescence was detected by plate reader via
excitation at 315 nM and emission at 400 nM.
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3.2.5 DNA Isolation
DNA was isolated using the Qiagen Kit per manufacturer’s instructions. Cultured
cells were harvested and resuspended in 200 µL of PBS with 20 µL proteinase K.
200 µL of buffer AL were added to the samples and vortexed. Cells were incubated
at 56°C for 10 minutes. 200 µL of ethanol were added to the samples and vortexed.
The mixture was pipetted into a DNeasy Mini spin column, centrifuged at 8000 rpm
for 1 minute, and the flow through discarded. The column was placed in a collection
tube, and 500 µL of buffer AW1 were added. The column was centrifuged at 8000
rpm for 1 minute, the flow through discarded, the column placed in a new collection
tube, and 500 µL of buffer AW2 were added. The column was centrifuged at 14,000
rpm for 3 minutes, the flow through discarded, and the column placed in 1.5 mL
microcentrifuge tube. 50 µL of AE buffer were added to the column, incubated for
10 minutes at room temperature, and centrifuged at 8,000 rpm for 1 minute. DNA
concentration was determined via Nanovue nanodrop (GE Healthcare).
3.2.6 DNA Repair Kinetics
Immuno slot blots were performed on whole cell lysates with 6,4 and CPD
antibodies via standard methods (Mellon et al., 2002). 100 ng of DNA was diluted
in 100 µL 1X Tris-ethylenediaminetetraacetic acid (EDTA) (TE) buffer to a
concentration of 1 ng/µL. Samples were heated at 95 °C for 8 minutes and
immediately placed on ice. Samples were diluted 1:1 with 100 µL of 20X salinesodium-phosphate-EDTA (SSPE) buffer for a final concentration of 0.5 ng/µL.
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Nitrocellulose membrane (BioRad) was wetted in distilled water and washed in 6X
SSPE. DNA was loaded onto nitrocellulose membrane on slot blot apparatus with
vacuum turned off. After all samples were loaded, the vacuum was turned on until
samples were pulled onto the membrane. Each well was then washed with 6X
SSPE. Membrane was heated at 80°C for 1 hour in a vacuum oven. After the
membrane cooled, it was re-wetted in 6X SSPE and rinsed with Tris buffered saline
(TBS) + 0.1% Tween (TBST) 2 times for 5 minutes each. Membrane was then
blocked in 1X TBST with 5% w/v nonfat dry milk for 1 hour. Membrane was
incubated with primary antibody at a dilution of 1:1000 in 1:1 solution of 1X TBST
with 5% w/v nonfat dry milk overnight at room temperature. Membrane was
washed for 5 minutes 4 times in 1X TBST. Membrane was incubated with HRP
conjugated anti-mouse secondary antibody (Abcam) in 1X TBST with 5% w/v
nonfat dry milk for 60 minutes. Membrane was washed with 1 X TBST for 5 minutes
4 times. Immunodetection was performed via chemiluminescence utilizing the ECL
Western Blotting Substrate (Thermo-Fisher). Immuno slot blots were scanned on
the STORM scanner (GE Healthcare). Membranes were analyzed using ImageJ.
3.2.7 Immunoblotting
Immunoblots were performed on whole cell lystates in radioimmunoprecipitation
assay (RIPA) buffer. Cells were lysed in RIPA buffer for 20 minutes at 4°C. Protein
concentration was determined via Bradford protein assay (Life Technologies).
Samples were diluted with 4X loading dye to a final concentration of 2X loading
dye and DTT to a final concentration of 1 nM. 10-30 µg of protein were loaded onto
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a 7-20% gradient sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE)
(BioRad). Gel was run at 200 V for 40 minutes in running buffer (25 mM Tris, 192
mM glycine, 0.1% SDS). Polyvinylidene fluoride (PVDF) membrane (Millipore) was
prepped prior to transfer. Membrane was wetted in 100% methanol for 30 seconds
and equilibrated in transfer buffer (48 mM Tris, 39 mM glycine, 0.037% SDS, 15%
methanol) for 20 minutes. Gel was equilibrated in transfer buffer for 5 minutes prior
to transfer. Protein was transferred overnight at 100 mAmp at room temperature.
Membrane was then blocked in 1:1 solution of Odyssey blocking buffer (LiCor):PBS for 1 hour. Membrane was incubated with primary antibody in 1:1
solution of Odyssey blocking buffer:PBS + 0.1% Tween (PBST) overnight at room
temperature. Membrane was washed for five minutes four times in PBST.
Membrane was incubated with anti-mouse (Molecular Probes) or anti-rabbit
secondary antibody (Li-Cor) in 1:1 solution of Odyssey blocking buffer:PBST +
0.01% SDS for 45 minutes. Membrane was washed with PBST for 5 minutes 4
times. Membrane was washed in PBS for 30 seconds twice and scanned on the
Odyssey (Li-Cor). Membranes were analyzed using ImageJ.
3.2.8 mRNA Isolation
Total RNA was harvested from cell culture using TRIzol (Life Technologies). Cells
were harvested in 500 µl of TRIzol. Sample was incubated for five minutes at room
temperature. 100 µL of chloroform were added to each sample, and each sample
was shaken vigorously for 15 seconds. Sample was incubated for 2–3 minutes at
room temperature. Sample was centrifuged at 12,000 × g for 15 minutes at 4°C.
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RNA was isolated in the aqueous phase. RNA was precipitated with 250 µL of
isopropanol. Sample was incubated at room temperature for 10 minutes and then
centrifuged at 12,000 × g for 10 minutes at 4°C. Supernatant was removed. The
RNA pellet was washed with 500 µL of ethanol and centrifuged at 7,500 × g for 5
minutes at 4°C. Supernatant was removed and the RNA pellet was dissolved in 50
µL RNase DNase free distilled water. RNA concentration was determined utilizing
a Nanovue nanodrop (GE Healthcare).
3.2.9 Reverse Transcriptase Polymerase Chain Reaction (RTPCR)
1 µg of RNA was reverse transcribed to cDNA utilizing random hexamers and MMLV reverse transcriptase (Promega) in a Mastercycler epgradient thermocycler
(Eppendorf International). cDNA was diluted 1:10 in RNase DNase free distilled
water for use in quantitative real time polymerase chain reaction.
3.2.10 Quantitative Real Time Polymerase Chain Reaction (qRTPCR)
Quantitative real time real time polymerase chain reaction (qRTPCR) analysis was
performed using an Applied Biosystems 7500 Real Time PCR System (Life
Technologies) (10 ng cDNA/reaction) utilizing TATA-binding protein (TBP) as a
reference gene. Primer sets for DCT were 5’- AACCAAAGCCACCAGTGTTC-3’
(right)

and

5’-GGTTCCTTTCTTCCCTCCAG-3’

(left),

MART1

were

5’-

ATAAGCAGGTGGAGCATTGG-3’ (right) and 5’- GCTCATCGGCTGTTGGTATT3’ (left), for Mitf were 5’-TACTTGGTGGGGTTTTCGAG- 3’ (right) and 5’AACTCATGCGTGAGCAGATG-3’

(left),
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for

PMEL17

5’-

AACCAAAAGCCACCAGTGTTC-3’ (right) and 5’-GGTTCCTTTCTTCCCTCCAG3’,

for

TBP

were

5 -́ CAGCGTGACTGTGAGTTGCT

TGGTTCATGGGGAAAAACAT

(right),

and

for

(left)

TYR

and
were

5 -́
5 -́

TACGGCGTAATCCTGGAAAC (left) and 5 -́ ATTGTGCATGCTGCTTTGAG (right)
(Integrated DNA Technologies).
3.2.11 Statistics and Data Analysis
One-way ANOVA with Tukey post-hoc test and two-way paired ANOVA analysis
were performed using GraphPad Prism 5.0 (GraphPad Software). Data were
considered statistically significant if p values were less than 0.05 from multiple
independent experiments.
3.3 Results
3.3.1 MITF Inhibition Does Not Affect NER Kinetics
In order to determine whether MITF plays a role in the acceleration of NER as
mediated by ATR, we first addressed whether MITF affected phosphorylation of
ATR. SK-MEL-2 melanoma cells or primary human melanocytes (PHMs) were pretreated with either scrambled or siRNA directed to MITF before incubation with 10
µM forskolin, an activator of adenylyl cyclase. Accumulation of pSer435-ATR was
measured by kinase assay as previously described (Jarrett et al., 2014). Treatment
with forskolin caused a 6.0-fold and 4.0-fold induction of ATR phosphorylation of
Ser435 in SK-MEL-2 (Figure 3.1 A) or PHMs (Figure 3.1 B) respectively, and levels
of pSer435-ATR were not influenced by MITF knockdown (Figure 3.1 A, 3.1 B). d
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Figure 3.1 MITF Inhibition Does Not Affect PKA Phosphorylation of ATR
A-B) SK-MEL-2 melanoma cells (n = 3 independent experiments) (A) and
PHMs (n = 4 independent experiments performed in 2 cell lines) (B) were
treated with scrambled siRNA or siRNA directed to MITF prior to
treatment with 10 µM forskolin. Whole cell lysates were collected at 1
hour. pSer435-ATR levels were determined by kinase assay. MITF
knockdown following treatment with siRNA directed to MITF is shown in
inset (representative image of 3 independent experiments for SK-MEL-2
melanoma cells (A) and 4 independent experiments for 2 PHM cell lines
(B)). Graph in A is representative of 3 independent experiments
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performed in SK-MEL-2 melanoma cells. Graph in B is representative of
4 independent experiments performed in 2 PHM cell lines. *p<0.05
compared to control as determined by one-way ANOVA and Tukey posthoc test. Data are expressed as mean fold change over control ± SEM.
Experiments were performed in collaboration with Dr. Stuart Jarrett,
Ph.D.

70

To determine directly whether MITF was required for MC1R-enhanced NER, we
measured the effect of MITF inhibition on basal and cAMP-enhanced NER. SKMEL-2 cells were treated with 0.1% vehicle control or 10 µM forskolin for 30
minutes prior to exposure to a sub-lethal dose (10 J/m2) of UVB radiation, and
repair of CPDs was assessed at 0, 24, 48, and 72 hours. Treatment with forskolin
significantly accelerated NER at 48 and 72 hours in SK-MEL-2 cells (Figure 3.2 A)
and 24, 48, and 72 hours in PHMs (Figure 3.2 B) with and without the presence of
MITF. We then directly compared the NER kinetics between cells with and without
MITF knockdown. Neither basal repair kinetics (Figure 3.2 C, 3.2 E) nor forskolin
enhanced repair (Figure 3.2 D, 3.2 F) were affected by MITF knockdown in either
cells. These data suggest that MITF is dispensable for MC1R-induced NER
enhancement.
3.3.2 ATR is Not Required for PKA Phosphorylation of CREB
We next determined whether ATR was required for other signaling events
downstream of MC1R. Treatment of SK-MEL-2 cells (Figure 3.3 A, 3.3 B) or PHMs
(Figure 3.3 C, 3.3 D) with 10 µM forskolin for 1 hour significantly increased PKA
phosphorylation of CREB at Ser133 (2.4-fold induction for melanoma cell lines;
2.6-fold induction for PHM). Inhibition of ATR kinase function via treatment with 10
µM VE-821 did not prevent the forskolin induction of pSer133-CREB in either SKMEL-2 cells (Figure 3.3 A, 3.3 B) or PHMs (Figure 3.3 C, 3.3 D). pSer317-Chk1
levels were decreased following treatment with VE-821 in UV-irradiated SK-MEL2 cells (Figure 3.3 E) and PHMs (Figure 3.3 F) confirming ATR kinase function was
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Figure 3.2 MITF Inhibition Does Not Affect NER Kinetics
A-F) Kinetics of CPDs were determined in SK-MEL-2 melanoma cells
(n = 4 independent experiments) (A, C, D) and PHMs (n = 4 independent
experiments performed in 2 cell lines) (B, E, F). Cells were treated with
scrambled siRNA or siRNA directed to MITF. Cells were treated with 10
µM forskolin for 30 minutes prior to treatment with 10 J/m2 UVB radiation.
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MITF knockdown following treatment with siRNA directed to MITF is
shown in inset (representative image of 4 independent experiments for
SK-MEL-2 melanoma cells (A) and 4 independent experiments
performed in 2 PHM cell lines (B)). Graphs in A, C, and D are
representative of 4 independent experiments performed in SK-MEL-2
melanoma cells. Graphs in B, E, and F are representative of 4
independent experiments performed in 2 PHM cell lines. *p < 0.05 as
determined by two-way paired ANOVA (p<0.05). Data are expressed as
mean %CPD remaining ± SEM. Experiments were performed in
collaboration with Dr. Stuart Jarrett, PhD.
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Figure 3.3 ATR Inhbition Does Not Affect PKA Phosphorylation of CREB
A-D) SK-MEL-2 melanoma cells (n = 3 independent experiments) (A-B)
and PHMs (n = 3 independent experiments performed in 2 PHM cell
lines) (C-D) were treated with 10 µM forskolin, 10 µM VE821, or a
combination of 10 µM forskolin and 10 µM VE-821. Whole cell lysates
were collected 1 hour following treatment and immunoblotted for
pSer133-CREB. Western blots displayed are representative images from
3 independent experiments (A – SK-MEL-2; B – PHMs). Quantification
of immunoblots for 3 independent experiments for SK-MEL-2 melanoma
cells is represented in B. Quantification of immunoblots for 3 independent
experiments performed in 2 PHM cell lines is represented in D. Values
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not sharing a common letter are significantly different as determined by
one-way ANOVA and Tukey post hoc test (p<0.05). Data are expressed
as mean fold change over control ± SEM. Data are expressed as mean
fold change over control ± SEM.
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Figure 3.4 VE-821 Inhibits ATR Kinase Function
A-B) SK-MEL-2 melanoma cells (n = 3 independent experiments) (A) and
PHMs (n = 4 independent experiments performed in 2 PHM cell lines)
(B) were pre-treated with 0.1% vehicle control or 10 µM Ve-821 for 30
minutes prior to treatment with 100 J/m2 UVB. Whole cell lysates were
collected 1 hour following UV treatment and immunoblotted for pSer317Chk1. Western blots displayed are representative images from 3
independent experiments (A – SK-MEL-2) and 4 independent
experiments performed in 2 PHM cell lines (B – PHMs).
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inhibited by VE-821. To further confirm ATR was not required for PKA
phosphorylation of CREB, SK- MEL-2 melanoma cells were treated with either a
scrambled control siRNA or siRNA directed to ATR prior to treatment with 10 µM
forskolin. Forskolin resulted in a 1.6-fold induction of CREB phosphorylation in SKMEL-2 cells (Figure 3.5 A, 3.5 B). Similar to results seen with the inhibition of ATR
kinase function by VE-821, ATR knockdown also did not prevent the
phosphorylation of CREB (1.6-fold induction) (Figure 3.4 A, 3.4 B). These results
suggest that ATR is not required for PKA-mediated CREB phosphorylation
downstream of cAMP induction.
3.3.3 ATR Kinase Function is Required for MITF Dependent Transcription
To determine whether ATR is required for cAMP-mediated induction of genes
required for melanin biosynthesis, we assessed the effect of ATR inhibition on
cAMP-induced pigment enzyme gene expression. SK-MEL-2 cells were treated
with 10 µM forskolin in the presence or absence of ATR inhibitor (10 µM VE-821)
for 48 hours and gene expression assessed via quantitative real time PCR.
Treatment with forskolin led to the induction of two pigment genes downstream of
MITF (DCT [2.5-fold], TYR [1.3-fold]) (Figure 3.6 A). We also assessed the effect
of forskolin on two additional MITF dependent genes, MART1 and PMEL17, which
are present in melanosomes. Treatment with forskolin resulted in a 2.2-fold
induction of MART1 gene expression and a 2.3-fold induction of PMEL17 gene
expression (Figure 3.6 A). Although treatment with VE-821 did not affect the basal
levels of the four genes (DCT [1.0-fold], MART1 [1.1-fold], PMEl17 [0.9-fold], TYR
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Figure 3.5 ATR Knockdown Does Not Affect PKA Phosphorylation of
CREB
A-B) SK-MEL-2 melanoma cells (n = 3 independent experiments) were
treated with scrambled siRNA or siRNA directed to ATR prior to treatment
with 10 µM forskolin. Whole cell lysates were collected 1 hour following
treatment and immunoblotted for pSer133-CREB. Western blot
displayed is a representative image from 3 independent experiments.
Quantification of immunoblots for 3 independent experiments for SKMEL-2 melanoma cells is represented in B. Quantification of
immunoblots for 3 independent experiments performed in 2 PHM cell
lines is represented in D. *p<0.05 compared to control as determined by
one-way ANOVA and Tukey post-hoc test. Data are expressed as mean
fold change over control ± SEM.
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Figure 3.6 ATR Inhibition Prevents cAMP Induced Expression of Pigment
Genes
A) SK-MEL-2 (n = 3 independent experiments) melanoma cells were
treated with 10 µM forskolin, 10 µM VE-821, or a combination of 10 µM
forskolin and 10 µM VE-821. DCT, TYR, MART1, and PMEL17 gene
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expression was determined 48 hours following treatment. qRTPCR was
performed in duplicate for each sample.
B) SK-MEL-2 (n = 3 independent experiments) melanoma cells were
treated with 10 µM forskolin, 10 µM VE-821, or a combination of 10 µM
forskolin and 10 µM VE-821. Mitf gene expression was determined 48
hours following treatment. qRTPCR was performed in duplicate for each
sample.
C) PHM (n = 4 independent experiments performed in 2 PHM cell lines)
were treated with 10 µM forskolin, 10 µM VE-821, or a combination of 10
µM forskolin and 10 µM VE-821. Mitf gene expression was determined
48 hours following treatment. qRTPCR was performed in duplicate for
each sample.
*p<0.05 treatment compared to control as determined by one-way
ANOVA and Tukey post-hoc test. #p<0.05 forskolin treatment compared
to forskolin + VE-821 as determined by one-way ANOVA and Tukey posthoc test. Data are expressed as mean fold change over control ± SEM.
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[1.0-fold]), inhibition of ATR kinase activity prevented the cAMP induction of all four
genes (DCT [1.4-fold], MART1 [1.6-fold], PMEL17 [1.3-fold], TYR [1.0- fold])
(Figure 3.6 A).
Because the induction of all four genes is dependent upon MITF activity (Levy et
al., 2006), we tested whether VE-821 affected Mitf transcription in SK-MEL-2 cells
and PHMs following treatment with 10 µM forskolin in the presence or absence of
ATR inhibitor (10 µM VE- 821). Similar to the induction of MITF-dependent genes,
treatment with forskolin resulted in a 1.4-fold induction of Mitf transcription 48 hours
following treatment in SK-MEL-2 cells (Figure 3.6 B) and a 1.3-fold induction in
PHMs (Figure 3.6 C). Inhibition of ATR with VE-821 did not affect basal MITF
mRNA levels, however, it did prevent cAMP-mediated enhancement in Mitf
expression in both melanoma (0.8-fold) (Figure 3.6 B) and PHM (0.9-fold) (Figure
3.6 C) cell lines, suggesting that ATR is needed for cAMP-mediated up-regulation
of Mitf expression.
3.4 Conclusions/Discussion
Herein we report that MITF does not appear to be required for MC1R-enhanced
NER. MITF has the potential to affect MC1R-enhanced NER via multiple
mechanisms. It functions as a transcription factor regulating genes involved in NER
(Strub et al., 2011). In addition, MITF has also been shown to interact with and
stabilize kinases, specifically the kinase Wnt (Rodriquez and Setaluri et al., 2014).
It is possible, therefore, that MITF could assist in ATR stabilization indirectly
affecting its kinase function. Despite these possibilities, MITF does not appear to
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be necessary for pSer435-ATR accumulation, the critical molecular event on which
MC1R-enhanced NER depends. Likewise, MITF inhibition had no impact on CPD
clearance in the three cell lines tested, suggesting that MITF does not regulate
basal NER or MC1R-enhanced genome maintenance.
In contrast, our data suggest that ATR may be important to MITF and pigment
enzyme induction downstream of MC1R signaling. Although inhibition of ATR
kinase activity or ATR knockdown did not affect phosphorylation of CREB by PKA,
inhibition of ATR kinase activity did prevent cAMP induction of Mitf gene
transcription and transcription of MITF dependent pigment genes. Inhibition of ATR
kinase activity did not lead to a significant alteration in basal Mitf gene levels or
MITF dependent pigment genes, suggesting that ATR kinase activity is only
necessary for activation of the adaptive pigmentation pathway and not for basal
melanin synthesis. This observation is similar to the effect of ATR on NER kinetics
in that ATR inhibition does not affect basal NER but completely abrogates cAMP
accelerated NER (Jarrett et al., 2014). Because ATR did not prevent PKA
phosphorylation of CREB, ATR appears to function downstream of PKA in the
activation of the adaptive pigmentation pathway following cAMP stimulus and may
be at the level of Mitf transcription. It is possible that the effect of ATR on Mitf
transcription is due to an indirect or global effect, however, ATR to our knowledge
has not yet been shown to have a role in the regulation of transcription of mRNA.
It is also possible that the effect may due to direct modification of CREB or MITF
by ATR. Future studies will determine whether the inhibition of the induction of
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pigment genes is due to a direct or indirect effect, and our current data do not
preclude either mechanism.
In summary, we have identified an additional interaction between the induction of
eumelanin synthesis and acceleration of NER downstream of MC1R. Although
only eumelanin synthesis and not the acceleration of NER appears to be
influenced by MITF function, both pathways appear to depend upon ATR kinase
activity. These findings support a broad role for ATR in MC1R-mediated
melanocyte UV adaptive responses.

Copyright © Erin Marissa Wolf Horrell 2016
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________________________________________________________________________
Chapter 4: The Effect of Rapamycin on the MC1R Dependent
Signaling Pathways
________________________________________________________________
4.1 Introduction
Malignant cutaneous melanoma is a highly metastatic disease that causes
approximately 75,000 deaths per year in the United States alone (Howlander et
al., 2016). A majority of melanoma diagnoses result from mutations following
exposure to carcinogenic ultraviolet (UV) radiation and damage of DNA bases
(Brash et al., 1991; Hodis et al., 2012, Shain et al., 2015). Activation of the
melanocortin 1 receptor (MC1R) signaling axis is a major innate defense
mechanism to protect the skin from the harmful effects UV radiation by both
preventing UV damage via the induction of eumelanin synthesis (Suzuki et al.,
1997) and accelerating the repair of UV induced DNA lesions (Abdel-Malek et al.,
2006; Hauser et al., 2006; Kadekaro et al., 2012; Jagirdar et al., 2013; Jarrett et
al., 2014). Individuals with loss of function MC1R polymorphisms exhibit fair skin,
have increased UV sensitivity, and a four fold increased risk of developing
melanoma compared to the general population (Valverde et al., 1995). In addition
to sustaining a larger degree of UV induced damage, individuals with a defective
MC1R signaling axis also cannot repair their DNA as efficiently, and therefore
acquire a greater number of mutations (Hauser et al., 2006; Jarrett et al., 2014).
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Pharmacologic manipulation of the MC1R signaling axis in order to augment the
protective signaling pathways is a major strategy to prevent UV induced melanoma
(D’Orazio et al., 2006; Abdel-Malek et al., 2010; Khaled et al., 2010). Augmentation
of the MC1R axis can occur either via direct activation of wild-type receptors
utilizing MC1R ligand analogs (Abdel-Malek et al., 2010) or via augmentation of
cAMP levels downstream of MC1R through activation of adenyly cylcase
(forskolin) or inhibition of phosphodiesterase inhibitors (rolipram) (D’Orazio et al.,
2006; Khaled et al., 2010; Jarrett et al., 2014). In addition to activating the UV
protective mechanisms, pharmacologic augmentation of the MC1R signaling axis
has a potentially dangerous consequence, increased melanocyte proliferation
(Suzuki et al., 1996; Kadekaro et al., 2003). Innately, the receptor has three
endogenous ligands: the positive agonist α melanocyte stimulating hormone
(αMSH) (Abdel-Malek et al., 2000), the negative agonist agouti signaling protein
(ASIP) (Blanchard et al., 1995), and the neutral antagonist β-defensin 3 (βD3)
(Candille et al., 2007), which regulate MC1R activity and function. In addition, like
most G protein coupled receptors, activation of MC1R via ligand binding results in
desensitization (Sanchez-Mas et al., 2005) and internalization (Sanchez-Laorden
et al., 2007) of the receptor preventing the receptor from constant activation.
Pharmacologic manipulation that bypasses the regulatory controls could result in
unrestrained melanocyte proliferation increasing the potential for malignant
transformation.
The mechanistic target of rapamycin (mTOR) has been shown to play a role in
proliferation in numerous physiological and pathological situations (Laplante and
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Sabatini, 2012). mTOR is a member of the phosphatidyl inositol 3 kinase like
kinase (PIKK) family (Lovejoy and Cortez, 2009), and MC1R and cAMP have been
shown to affect the signaling of multiple members of the PIKK family including
ataxia telangiectasia mutated (ATM) protein (Swope et al., 2014), ataxia
telangiectasia mutated and Rad3 related (ATR) protein (Kadekaro et al., 2012;
Jarrett et al., 2014; Swope et al., 2014), and DNA protein kinase (DNA-PK)
(Kadekaro et al., 2012). In general, mTOR functions as a nutrient sensor, and
activation of mTOR complex 1 (mTORC1) regulates a complex series of signaling
events, including enhancing cell growth and proliferation (Laplante and Sabatini
2012).
In this paper we report that cAMP induced proliferation is sensitive to low doses of
rapamycin, an inhibitor of mTORC1, and that rapamycin does not prevent cAMP
induced eumelanin synthesis or the acceleration of DNA repair. Our findings
suggest that it is possible via a combination of pharmacologic treatments to
selectively enhance the MC1R protective pathways without the risk of uncontrolled
proliferation.
4.2 Methods
4.2.1 Murine Model, Pigmentation, and UV Exposure
Murine experimental protocols were approved by the Institutional Animal Care and
Use Committee at the University of Kentucky. C57/BL/6JJ mice with a
nonfunctional MC1R protein were crossed with K14-Scf transgenic animals (K14-
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Scf-MC1Re/e) (D’Orazio et al., 2006) to generate mice with humanized skin whose
melanocytes were retained in the epidermis at the time of weaning. All murine
experiments were performed in K14-Scf-MC1Re/e mice.
For pigmentation experiments, mice were treated immediately after weaning. Mice
were randomized into groups, and groups were sex matched. Mice were shaved,
and the dorsal side of each mouse was divided into two non-overlapping regions.
The anterior region was treated with a topical application of 70% ethanol 30%
propylene glycol vehicle control. The posterior region was treated with a topical
application of 10% forskolin in 70% ethanol 30% propylene glycol vehicle or
combination of 10% forskolin and 1% rapamycin in 70% ethanol 30% propylene
glycol vehicle. The dose of rapamycin used was similar to experiments performed
in a mouse model of tuberous sclerosis utilizing a topical application of rapamycin
(Rauktys et al., 2008). Each treatment was performed daily for five days with a
two-day drug holiday for three weeks (22 days total). Skin reflective colorimetry
was performed for each region of each mouse prior to treatment on day 1 and then
prior to treatment on day 8, day 15, and day 22 after the two-day drug holiday.
Colorimetry was performed utilizing a CR-400 Colorimeter (Minolta Corporation).
Mice who had hair growth in the anagen phase were excluded from colorimetry
measurements as the darkly pigmented hair could not be removed and would
affect the measurements. The degree of pigmentation (darkness) was quantified
as the measurement on the *L axis (white-black axis) of the CIE standard color
axis and was determined by three independent measurements for each sample.
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For DNA repair experiments, mice ages ranged from 8 weeks – 14 weeks. Mice
were randomized into groups, and groups were age and sexed matched. Mice
were shaved, and the dorsal side of each mouse was treated with a topical
application of 70% ethanol 30% propylene glycol vehicle, 10% forskolin in 70%
ethanol 30% propylene glycol vehicle, or combination of 10% forskolin and 1%
rapamycin in 70% ethanol 30% propylene glycol vehicle once a day for the time
indicated. Mice were then treated with a one-time dose of 7.5 kJ/m2 UVB radiation
via an overhead double bank of UVB lamps (UV Products). UV radiation was
measured via a Model IL1400A handheld flash measurement photometer
(International Light) with a UVB filter (assessing wavelengths between 265-332 nm
with a peak response at 290 nm). 1 cm2 biopsies were taken at times indicated
following UV radiation.
4.2.2 Immunohistochemistry
All immunohistochemistry preparation, skin processing, and staining was
performed by the University of Kentucky Markey Cancer Center Biospecimen and
Tissue Procurement Shared Resource Facility. Skin biopsies were fixed in 4%
paraformaldehyde for 48 hours and subsequently placed in 70% ethanol. Biopsies
were embedded in paraffin and sectioned onto slides. Slides were stained with
Fontana Masson (Abcam) to assess melanin content. Slides were stained for Ki67
(Abcam) to assess proliferation. For Ki67 staining, antigen retrieval was performed
using citrate buffer (Dako).
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4.2.3 Cell Lines, Pharmacologic Treatments, and siRNA
Transformed SK-MEL-2 melanoma cells (ATCC) were cultured in Roswell Park
Memorial Institute (RMPI) media (Life Technologies) with 10% fetal bovine serum.
Forskolin

(LC

Laboratories),

rapamycin

(LC

Laboratories),

and

H-89

(Selleckchem) were utilized as indicated. siRNA targeted to raptor (Dharmacon),
rictor (Dharmacon), and p70 (Dharmacon) were performed according to the
manufacturer’s instructions.
4.2.4 Antibodies
Commercially available antibodies included anti-6,4 PP (Kamiya Biomedical), antiCPD (Kamiya Biomedical), anti-pSer2448-mTOR (Cell Signaling), anti-mTOR
(Cell Signaling), anti-pSer371-Akt (Cell Signaling), anti-Akt (Cell Signaling), antiraptor (Cell Signaling), anti-rictor (Cell Signaling), anti-p70S6K (Cell Signaling),
anti-ATR (Cell Signaling), and anti-PKA substrate (Cell Signaling).
4.2.5 In Vitro UV Exposure
Cells were treated with 0.1% ethanol vehicle, 10 µM forskolin, 1 nM rapamycin, or
a combination of 10 µM forskolin and 1 nM rapamycin as indicated for 1 hour prior
to UV exposure. UV radiation was measured via a Model IL1400A handheld flash
measurement photometer (International Light) with a UVB filter (assessing
wavelengths between 265-332 nm with a peak response at 290 nm). Media was
removed from the cells, and cells were exposed to a dose of 30 J/m2 UVB.
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4.2.6 Proliferation Studies
Proliferation was assessed via cell number and cell viability. For cell number, cells
were plated at a density of 5,000 cells/well in a 6 well plate. Cells were treated with
0.1% ethanol vehicle, 10 µM forskolin, 1 nM rapamycin, or a combination of 10 µM
forskolin and 1 nM rapamycin daily for 7 days. Cells were treated with 0.25%
trypsin for 5 minutes at 32°C and harvested. Cells were resuspended in 500 µL of
media. Cell count was manually determined ten times per sample.
Cell viability was assessed via the tetrazolium 3-(4, 5-dimethylthiazolyl-2)-2, 5diphenyltetrazolium bromide (MTT) cell proliferation assay. Cells were plated at a
density of 5,000 cells/well in a 24 well plate. Cells were treated with 0.1% ethanol
vehicle, 10 µM forskolin, 1 nM rapamycin, or a combination of 10 µM forskolin and
1 nM rapamycin daily for 4 days. The MTT substrate was prepared in phosphate
buffered saline (pH 7.4) at a concentration of 1 mg/mL. Media was aspirated from
the cells and 250 µL of MTT substrate was placed on each well. Cells were
incubated for 20 minutes at 32°C. MTT solution was removed, and 250 µL of
dimethyls sulfoxide (DMSO) was placed on each well to dissolve the MTT
substrate. 100 µL of DMSO dissolved substrate was placed into a 96 well plate,
and absorbance was assessed via plate reader at 560 nM excitation.
4.2.7 DNA Isolation
DNA was isolated using the Qiagen Kit per manufacturer’s instructions. For mouse
studies, 25-50 mg of tissue were placed in 180 µL of ATL buffer with 20 µL of
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proteinase K. Tissue was cut into small pieces and placed at 56°C overnight with
regular vortexing until completely lysed. Cultured cells were harvested and
resuspended in 200 µL of PBS with 20 µL proteinase K. 200 µL of buffer AL were
added to both cells and tissue samples and vortexed. Cells were incubated at 56°C
for 10 minutes. At this point, both tissue and cell culture samples were treated the
same. 200 µL of ethanol were added to the samples and vortexed. The mixture
was pipetted into a DNeasy Mini spin column and centrifuged at 8000 rpm for 1
minute. The flow through was discarded, and the column was placed in a new
collection tube. 500 µL of buffer AW1 was added to the column. The column was
centrifuged at 8000 rpm for 1 minute. The flow through was discarded, and the
column was placed in a new collection tube. 500 µL of buffer AW2 was added to
the column. The column was centrifuged at 14,000 rpm for 3 minutes. The flow
through was discarded, and the column was placed in 1.5 mL microcentrifuge tube.
50 µL of AE buffer was placed on the column and incubated for 10 minutes at room
temperature. The column was centrifuged at 8,000 rpm for 1 minute. DNA
concentration was determined via a Nanovue nanodrop (GE Healthcare).
4.2.8 DNA Repair Kinetics
Immuno slot blots were performed on whole cell lysates with 6,4 PP and CPD
antibodies via standard methods (Mellon et al., 2002). 100 ng of DNA was diluted
in 100 µL 1X 1X Tris-ethylenediaminetetraacetic acid (EDTA) (TE) buffer to a
concentration of 1 ng/µL. Samples were heated at 95 °C for 8 minutes and
immediately placed on ice. Samples were diluted 1:1 with 100 µL of 20X saline91

sodium-phosphate-EDTA (SSPE) buffer for a final concentration of 0.5 ng/µL.
Nitrocellulose membrane (Li-Cor) was wetted in distilled water and washed in 6X
SSPE. DNA was loaded onto nitrocellulose membrane on slot blot apparatus with
vacuum turned off. After all samples were loaded, the vacuum was turned on until
samples were pulled onto the membrane. Each well was then washed with 6X
SSPE. Membrane was heated at 80°C for 1 hour in a vacuum oven. After the
membrane cooled, it was re-wetted in 6X SSPE and rinsed with PBS + 0.1%
Tween (PBST) 2 times for 5 minutes each. Membrane was then blocked in 1:1
solution of Odyssey blocking buffer (Li-Cor):PBS for 1 hour. Membrane was
incubated with primary antibody at a dilution of 1:1000 in 1:1 solution of Odyssey
blocking buffer:PBST overnight at room temperature. Membrane was washed for
five minutes four times in PBST. Membrane was incubated with anti-mouse
secondary antibody (Licor) in 1:1 solution of Odyssey blocking buffer:PBST +
0.01% sodium dodecyl sufate (SDS) for 45 minutes. Membrane was washed with
PBST for 5 minutes 4 times. Membrane was washed in PBS for 30 seconds twice
and scanned on the Odyssey (Li-Cor). Membranes were analyzed using ImageJ.
4.2.9 Immunoprecipitation and Immunoblotting
Immunoblots were performed on whole cell lystates in radioimmunoprecipitation
assay (RIPA) buffer. Cells were lysed in RIPA buffer for 20 minutes at 4°C. Protein
concentration was determined via Bradford protein assay (Life Technologies).
Samples were diluted with 4X loading dye to a final concentration of 2X loading
dye and dithiothreitol (DTT) to a final concentration of 1 nM. 10-30 µg of protein
92

were loaded onto a 7-20% gradient SDS-polyacrylamide gel (SDS-PAGE). Gel
was run at 200 V for 40 minutes in running buffer (25 mM Tris, 192 mM glycine,
0.1% SDS). Polyvinylidene fluoride (PVDF) membrane (Millipore) was prepped
prior to transfer. Membrane was wetted in 100% methanol for 30 seconds and
equilibrated in transfer buffer (48 mM Tris, 39 mM glycine, 0.037% SDS, 15%
methanol) for 20 minutes. Gel was equilibrated in transfer buffer for 5 minutes prior
to transfer. Protein was transferred overnight at 100 mAmp at room temperature.
Membrane was then blocked in 1:1 solution of Odyssey blocking buffer:PBS for 1
hour. Membrane was incubated with primary antibody in 1:1 solution of Odyssey
blocking buffer:PBST overnight at room temperature. Membrane was washed for
5 minutes 4 times in PBST. Membrane was incubated with anti-mouse or antirabbit secondary antibody (Li-Cor) in 1:1 solution of Odyssey blocking buffer:PBST
+ 0.01% sodium dodecyl sufate (SDS) for 45 minutes. Membrane was washed with
PBST for 5 minutes 4 times. Membrane was washed in PBS for 30 seconds twice
and scanned on the Odyssey (Li-Cor).
Immunoprecipitations were performed in whole cell lysates in RIPA buffer. Whole
cell lysates were incubated with 5 µg of antibody overnight at 4°C. 20% of the
sample was removed for loading control immunoblot. 100 µL of beads were
centrifuged at 5000 x g for 1 minute in a microcentrifuge, and the ethanol
supernatant removed. The beads were washed three times in PBS to remove
residual ethanol. Beads were dissolved in 100 µL of PBS and placed in the whole
cell lysates. Samples rotated at 4°C for 2 hours. Samples were diluted with 4X
loading dye to a final concentration of 2X and DTT to a final concentration of 1 nM.
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Samples were centrifuged in a microcentrifuge for 1 minute prior to
immunoblotting.
4.2.10 RNA Isolation
Total RNA was harvested from cell culture using TRIzol (Life Technologies). Cells
were harvested in 500 µl of TRIzol. Sample was incubated for five minutes at room
temperature. 100 µL of chloroform were added to each sample, and each sample
was shaken vigorously for 15 seconds. Sample was incubated for 2–3 minutes at
room temperature. Sample was centrifuged at 12,000 × g for 15 minutes at 4°C.
RNA was isolated in the aqueous phase. RNA was precipitated with 250 µL of
isopropanol. Sample was incubated at room temperature for 10 minutes and then
centrifuged at 12,000 × g for 10 minutes at 4°C. Supernatant was removed. The
RNA pellet was washed with 500 µL of ethanol and centrifuged at 7,500 × g for 5
minutes at 4°C. Supernatant was removed, and the RNA pellet was dissolved in
50 µL RNase DNase free dstilled water. RNA concentration was determined
utilizing a Nanovue nanodrop (GE Healthcare).
4.2.11 Reverse Transcriptase Polymerase Chain Reaction (RTPCR)
1 µg of RNA was reverse transcribed to cDNA utilizing random hexamers and MMLV reverse transcriptase (Promega) in a Mastercycler epgradient thermocycler
(Eppendorf International). cDNA was diluted 1:10 in RNase DNase free distilled
water for use in quantitative real time polymerase chin reaction.
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4.2.12 Quantitative Real Time Polymerase Chain Reaction (qRTPCR)
Quantitative real time PCR (qRTPCR) analysis was performed using an Applied
Biosystems 7500 Real Time PCR System (Life Technologies) (10 ng
cDNA/reaction) utilizing TATA-binding protein (TBP) as a reference gene. Primer
sets

for

DCT

were

5’-AACCAAAGCCACCAGTGTTC-3’

GGTTCCTTTCTTCCCTCCAG-3’

(left),

MART1

(right)
were

and

5’5’-

ATAAGCAGGTGGAGCATTGG-3’ (right) and 5’-GCTCATCGGCTGTTGGTATT3’ (left), for PMEL17 5’-AACCAAAAGCCACCAGTGTTC-3’ (right) and 5’GGTTCCTTTCTTCCCTCCAG-3’,
CAGCGTGACTGTGAGTTGCT

for
(left)

and

TBP

were

5´-

5´-TGGTTCATGGGGAAAAACAT

(right), and for TYR were 5´-TACGGCGTAATCCTGGAAAC (left) and 5´ATTGTGCATGCTGCTTTGAG-3’ (right) (Integrated DNA Technologies).
4.2.13 Statistics and Data Analysis
Student’s T Test, two-way paired ANOVA analysis, and one-way ANOVA with
Tukey post-hoc test were performed using GraphPad Prism 5.0 (GraphPad
Software). Data were considered statistically significant if p values were less than
0.05 from multiple independent experiments.
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4.3 Results
4.3.1 cAMP Enhances mTOR Phosphorylation in an mTORC1 Dependent
Manner
We first determined whether cAMP stimulus could affect mTOR signaling.
Treatment of SK-MEL-2 cells with forskolin led to the phosphorylation of mTOR at
Ser2448 over 6 hours suggesting potential activation of mTOR complex 1
(mTORC1) (Figure 4.1 A and B). Treatment with forskolin, however, did not alter
phosphorylation of Akt at Ser371 suggesting mTOR complex 2 (mTORC2) was not
activated (Figure 4.1 C and D).
Phosphorylation of mTOR at Ser2448 can occur in an mTOR kinase dependent or
independent manner (Chiang and Abraham et al., 2005). To test whether the
mTOR phosphorylation event was dependent upon mTORC1 activity, we
assessed the role of the regulatory-associated protein of mammalian target of
rapamycin (raptor) (a component of mTORC1) (Hara et al., 2002; Kim et al., 2003)
on cAMP induced mTOR phosphorylation. SK-MEL-2 cells were treated with
scrambled siRNA or siRNA directed to raptor prior to forskolin treatment for 6
hours. Knock down of raptor prevented the forskolin induced pSer2448-mTOR
(Figure 4.1 E and F) suggesting forskolin induced mTOR phosphorylation is
dependent upon mTORC1 signaling. To confirm mTORC2 did not affect forskolin
dependent mTOR phosphorylation, we looked at the role of rapamycin insensitive
campanion of mTOR (rictor), a component of mTORC2 (Jacinto et al., 2004;
Sarbassov et al., 2004). SK-MEL-2 cells were treated with scrambled siRNA or
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Figure 4.1 cAMP Activates mTORC1 Independent of mTORC2
A-B) SK-MEL-2 melanoma cells (n = 3 independent experiments) were
treated with 0.1% ethanol vehicle or 10 µM forskolin. Whole cell lysates
were collected at 0.5, 1, 2, and 6 hours following treatment and
immunoblotted for pSer2448-mTOR. Western blots displayed are
representative

images

from

3

independent

experiments

(A).

Quantification of immunoblots for 3 independent experiments is
represented in B. Data are expressed as mean fold change over control
± SEM.
C-D) SK-MEL-2 melanoma cells (n = 3 independent experiments) were
treated with 0.1% ethanol vehicle or 10 µM forskolin. Whole cell lysates
were collected at 0.5, 1, 2, and 6 hours following treatment and
immunoblotted

for

pSer371-Akt.

representative

images

from

3

Western

blots

independent

displayed

are

experiments

(C).

Quantification of immunoblots for 3 independent experiments is
represented in D. Data are expressed as mean fold change over control
± SEM.
E-H) SK-MEL-2 melanoma cells (n=3) were treated with scrambled
siRNA or siRNA directed to raptor (E-F) or rictor (G-H) prior to treatment
with 10 µM forskolin. Whole cell lysates were collected 6 hours following
treatment and immunoblotted for pSer2448-mTOR. Western blots
displayed are representative images from 3 independent experiments (E,
G). Quantification of immunoblots for 3 independent experiments
melanoma cells is represented in B.
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*p < 0.05 as determined by

is represented in F and H. *p < 0.05 as determined by Student’s T Test
between the vehicle and forskolin treatment. Data are expressed as
mean fold change over control ± SEM.
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siRNA directed to rictor prior to forskolin treatment. Knock down of rictor did not
affect the forskolin induced pSer2448-mTOR (Figure 4.1 G and H) suggesting
forskolin induced mTOR phosphorylation is independent from mTORC2 signaling.
4.3.2 cAMP Induced mTOR Phosphorylation is Dependent Upon p70S6K
Phosphorylation of mTOR at Ser2448 can occur either via p70S6 kinase (p70S6K)
(Chiang and Abraham et al., 2005) or protein kinase B (Akt) (Nave et al., 1999;
Sekulic et al., 2000). Phosphorylation of mTOR at Ser2448 by p70S6K is
dependent upon mTOR kinase function and and is rapamycin sensitive (Chiang
and Abraham, 2005). In addition, p70S6K activity has been shown to be protein
kinase A (PKA) dependent (Cass et al. 1999). Phosphorylation of mTOR at
Ser2448 by Akt, however, is rapamycin insensitive (Chiang and Abraham, 2005),
and Akt function and activation has been shown to be PKA independent (Cass et
al., 1999). Because we observed that inhibition of mTORC1 prevented mTOR
phosphorylation at Ser2448, we hypothesized that p70S6K was responsible for
phosphorylating mTOR downstream of forskolin treatment.
To determine whether the phosphorylation event was sensitive to rapamycin, SKMEL-2 cells were treated with 10 µM forskolin, 1 nM rapamycin, or a combination
of 10 µM forskolin and 1 nM rapamycin for 6 hours. Treatment with forskolin
resulted in an increase in mTOR phosphorylation at Ser2448. Treatment with
rapamycin decreased basal pSer2448-mTOR and prevented the phosphorylation
of mTOR at Ser2448 downstream of forskolin (Figure 2.2 A and B). We next tested
whether pSer2448-mTOR was dependent upon PKA signaling. SK-MEL-2 cells
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Figure 4.2 p70S6K Phosphorylates mTOR at Ser2448 Downstream of
cAMP
A-B) SK-MEL-2 melanoma cells (n = 3 independent experiments) were
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treated with 0.1% ethanol vehicle, 10 µM forskolin, 1 nM rapamycin, or a
combination of 10 µM forskolin and 1 nM rapamycin. Whole cell lysates
were collected 6 hours following treatment and immunoblotted for
pSer2448-mTOR. Western blots displayed are representative images
from 3 independent experiments (A). Quantification of immunoblots for 3
independent experiments is represented in B. Values not sharing a
common letter are significantly different as determined by one-way
ANOVA and Tukey post hoc test (p<0.05). Data are expressed as mean
fold change over control ± SEM.
C-D) SK-MEL-2 melanoma cells (n = 3 independent experiments) were
treated with 0.1% ethanol or DMSO vehicle, 10 µM forskolin, 10 µM H89,
or a combination of 10 µM forskolin and 10 µM H89. Whole cell lysates
were collected 6 hours following treatment and immunoblotted for
pSer2448-mTOR. Western blots displayed are representative images
from 3 independent experiments (C). Quantification of immunoblots for 3
independent experiments is represented in D. Values not sharing a
common letter are significantly different as determined by one-way
ANOVA and Tukey post hoc test (p<0.05). Data are expressed as mean
fold change over control ± SEM.
E-F SK-MEL-2 melanoma cells (n = 3 independent experiments) were
treated with scrambled siRNA or siRNA directed to p70S6K prior to
treatment with 10 µM forskolin. Whole cell lysates were collected 6 hours
following

treatment

and

immunoblotted
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for

pSer2448-mTOR.

Western blots displayed are representative images from 3 independent
experiments (E). Quantification of immunoblots for 3 independent
experiments is represented in F. *p < 0.05 as determined by Student’s T
Test between the vehicle and forskolin treatment. Data are expressed as
mean fold change over control ± SEM.
G-J Coimmunoprecipitation experiments were performed in SK-MEL-2
melanoma cells (n=3) with anti-Akt (G), anti-p70S6K (H), anti-mTOR (I),
and anti-ATR (J) and immunoblotted for anti-PKA substrate. Input
represents 10% of total lysates.
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were treated with 10 µM forskolin,10 µM H-89, an inhibitor of PKA signaling, or a
combination of 10 µM forskolin and 10 µM H-89 for 6 hours. Treatment with H-89
decreased basal pSer2448-mTOR and prevented the forskolin induced pSer2448mTOR (Figure 2.2 C and D).
Finally, we directly tested whether p70S6K was responsible for mTOR
phosphorylation downstream of cAMP stimulus. SK-MEL-2 melanoma cells were
treated with scrambled siRNA or siRNA directed to p70S6K prior to treatment with
forskolin for 6 hours. Knockdown of p70S6K prevented the phosphorylation of
mTOR at Ser2448 after forskolin treatment (Figure 2.2 E and F) confirming that
p70S6K phosphorylates mTOR downstream of cAMP accumulation.
Because phosphorylation of mTOR by p70S6K was PKA dependent downstream
of cAMP, we tested whether PKA could directly phosphorylate components of the
mTOR signaling pathway, specifically mTOR, Akt, and p70S6K. SK-MEL-2
melanoma cells were treated with forskolin for 1 hour. An immunoprecipitation was
performed on whole cell lysates for mTOR, Akt, and p70S6K and immunoblotted
for the PKA substrate antibody that recognizes sites that have undergone PKA
phosphorylation. As a positive control, we also assessed the phosphorylation of
ATR following cAMP stimulus as we previously reported it is phosphorylated by
PKA (Jarrett et al., 2014). PKA did not directly phosphorylate Akt (Figure 4.2 G),
p70S6K (Figure 4.2 H), or mTOR (Figure 4.2 I) but did phosphorylate ATR (Figure
4.2 J) following cAMP stimulus suggesting that there is an additional protein which
is activated by cAMP that regulates mTORC1 activity.
104

4.3.3 cAMP Induced Proliferation is Rapamycin Sensitive
Given that mTOR is known to affect proliferation and that cAMP stimulus altered
mTOR activity in a rapamycin sensitive manner, we tested the effect of rapamycin
on cAMP induced proliferation in SK-MEL-2 melanoma cells. Treatment of cells
with forskolin for 7 days led to an increase in proliferation as assessed by cell
number. Treatment with a low dose of rapamycin (1 nM) led to a slight decrease
in basal proliferation and prevented the forskolin induced proliferation (Figure 4.3
A). We then confirmed the effect of rapamycin on forskolin induced proliferation
via MTT. Forskolin led to an increase in cell viability in SK-MEL-2 cells after 4 days
of treatment. Similar to the effects seen with cell number, treatment with rapamycin
caused a slight decrease in basal cell viability and prevented the forskolin induced
proliferation (Figure 4.3 B) suggesting that cAMP induced proliferation in
melanocytes is dependent upon mTOR activity.
4.3.4 MC1R Induced UV Protective Pathways Are Rapamycin Insensitive In
Vitro
To determine whether it would be possible to selectively augment the MC1R
protective pathways without the risk of proliferation, we assessed whether
simultaneous treatment of rapamycin and forskolin affected the induction of
eumelanin synthesis and acceleration of NER in vitro. We first determined the
effect of rapamycin on the induction of microphthalmia-associated transcription
factor (MITF) dependent genes involved in pigmentation. SK-MEL-2 melanoma
cells were treated with 10 µM forskolin, 1 nM rapamycin, or a combination of 10
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Figure 4.3 cAMP Induced Proliferation is Rapamycin Sensitive
A) SK-MEL-2 melanoma cells (n = 3 independent experiments) were
treated with 0.1% ethanol vehicle, 10 µM forskolin, 1 nM rapamycin, or a
combination of 10 µM forskolin and 1 nM rapamycin for 7 days.
Proliferation was assessed by cell count.
B) SK-MEL-2 melanoma cells (n = 3 independent experiments) were
treated with ethanol vehicle, 10 µM forskolin, 1 nM rapamycin, or a
combination of 10 µM forskolin and 1 nM rapamycin for 4 days. Cell
viability was assessed via MTT reaction.
Values not sharing a common letter are significantly different as
determined by one-way ANOVA and Tukey post hoc test (p<0.05). Data
are expressed as mean fold change over control ± SEM.
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µM forskolin and 1 nM rapamycin for 48 hours. Treatment with forskolin resulted
in an increase in expression for four MITF dependent genes: DCT, MART1,
PMEL17, and TYR. Treatment with rapamycin did not affect basal gene
transcription. It also did not prevent the forskolin dependent induction of MITF
dependent genes, and for MART1 and TYR, the combination of forskolin and
rapamycin resulted in enhanced gene transcription above forskolin treatment
alone (Figure 4.4 A).
To determine whether rapamycin prevented forskolin enhanced NER, SK-MEL-2
cells were treated with 10 µM forskolin, 1 nM rapamycin, or a combination of 10
µM forskolin and 1 nM rapamycin for 1 hour prior to treatment with 30 J/m2 UVB
radiation. Clearance of cyclobutanedipyrimidine dimers (CPDs) was assessed at
0, 24, and 48 hours following UV treatment. Treatment with forskolin significantly
accelerated repair of CPDs at 24 and 48 hours, and rapamycin treatment alone
did not affect basal NER kinetics, nor did it inhibit forskolin accelerated repair
(Figure 4.4 B). These data suggest it may be possible to utilize a combination of
pharmacologic drugs to activate MC1R pathways and prevent the induction of
proliferation.
4.3.5 Selective Activation of MC1R Protective Pathways In Vivo
In order to test whether it is possible to selectively augment the MC1R protective
pathways in vivo, we utilized a murine model with humanized skin due to
expression of a K14-Scf transgene with a non-functional MC1R protein (K14-ScfMC1Re/e). The expression of Scf results in melanocyte retention in the epidermis.
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Figure 4.4 Rapamycin Does Not Prevent cAMP Induced Eumelanin
Synthesis or Acceleration of NER In Vitro
A) SK-MEL-2 (n = 3 independent experiments) melanoma cells were
treated with 0.1% ethanol vehicle, 10 µM forskolin, 10 nM rapamycin , or
a combination of 10 µM forskolin and 1 nM rapamycin. DCT, TYR,
MART1, and PMEL17 gene expression was determined 48 hours
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following treatment. qRTPCR was performed in duplicate for each
sample. Values not sharing a common letter are significantly different as
determined by one-way ANOVA and Tukey post hoc test (p<0.05). Data
are expressed as mean fold change over control ± SEM.
B) Kinetics of CPDs were determined in SK-MEL-2 melanoma cells (n =
5 independent experiments). Cells were treated with 0.1% ethanol
vehicle, 10 µM forskolin, 10 nM rapamycin , or a combination of 10 µM
forskolin and 1 nM rapamycin for 1 hour prior to treatment with 30 J/m2
UVB radiation. Kinetics were assessed at 0, 24, and 48 hours following
UV exposure. Values not sharing a common letter are significantly
different as determined by two-way paired ANOVA (p<0.05). Data are
expressed as mean percent CPD remaining ± SEM.
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Previous studies have demonstrated that topical treatment of the K14-Scf-MC1Re/e
mice with forskolin can induce tanning of the skin downstream of MC1R (D’Orazio
et al., 2006) suggesting that these mice are a useful model to study augmentation
of the MC1R pathway. We first tested whether whether rapamycin affected cAMP
induced proliferation in an in vivo setting. Each mouse was shaved, and the dorsal
region of the mouse was divided into to two non-overlapping regions. The anterior
dorsal region was treated with a 70% propylene rapamycin in 70% propylene glycol
30% ethanol, and the posterior dorsal region was treated with 10% forskolin in 70%
propylene glycol 30% ethanol vehicle or 10% forskolin + 1% rapamycin in 70%
propylene glycol 30% ethanol vehicle for three weeks. Skin biopsies were taken at
day 22 and processed for immunohistochemistry. Treatment with forskolin led to
an increase in epidermal cell proliferation as assessed by staining for Ki67 which
was prevented by simultaneous treatment with rapamycin (Figure 4.5 A).
We next assessed whether rapamycin affected forskolin induced eumelanin
synthesis in vivo. Each mouse was shaved, and the dorsal region of the mouse
was divided into to non-overlapping regions. The anterior dorsal region was treated
with a 70% propylene glycol 30% ethanol vehicle control, and the posterior dorsal
region was treated with 10% forskolin in 70% propylene glycol 30% ethanol vehicle
or 10% forskolin + 1% rapamycin in 70% propylene glycol 30% ethanol vehicle for
three weeks. Topical application of forksolin lead to an induction of melanin
synthesis over the three weeks as measured by reflective colorimetry (Figure 4.5
B). Simultaneous treatment with rapamycin did not prevent forksolin induction of
pigment over three weeks (Figure 4.5 B). To confirm rapamycin did not affect
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Figure 4.5 Rapamycin Prevents Proliferation But Does Not Affect cAMP
Induced Eumelanin Synthesis In Vivo
A-C) K14-Scf MC1R

e/e

mice (n=6 per group) were treated for 3 weeks

with a topical application of 70% ethanol 30% propylene glycol, 10%
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forskolin, or a combination of 10% forskolin and 1% rapamycin.
(A) Histological analysis of mouse skin samples following 3 weeks of
topical forskolin. Tissues were stained for Ki67 to assess proliferation.
Images presented are representative of 6 independent experiments.
(B) Degree of skin pigmentation was calculated via *L score vehicle - *L
score treatment for each mouse (n=3-6 per time point). Data are
expressed as mean ± SEM.
(C) Histological analysis of mouse skin samples following 3 weeks of
topical forskolin. Tissues were stained via the Fontana Masson stain to
assess eumelanin production. Images presented are representative of 6
independent experiments.
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pigment induction, skin biopsies were obtained at three weeks following treatment
and processed for immunohistochemistry. Samples were stained for melanin via
the Fontana Masson (FM) stain. Treatment with forskolin led to an increase in FM
stain, and simultaneous treatment with rapamycin did not prevent the induction
(Figure 4.5 C).
In order to determine whether rapamycin affected cAMP induced acceleration of
NER kinetics, we first further characterized the NER kinetics in the K14-ScfMC1Re/e mice. We previously reported that treatment with forskolin for five days
accelerated repair of CPDs in the K14-Scf-MC1Re/e mice, however, we did not
determine the effect on pyrimidine 6,4 pyrimidone photoproducts (6,4 PPs) (Jarrett
et al., 2014). We characterized the innate repair kinetics of 6,4 PPs and CPDs in
the K14-Scf-MC1Re/e mouse model. Repair of 6,4 PPs occurred faster than CPDs
and were nearly 100% removed by 72 hours (Figure 4.6 A). In contrast, at 72
hours, only 70% of CPDs had been repaired (Figure 4.6 B).
Previous in vitro and in vivo studies have demonstrated that MC1R activation is
required prior to exposure to UV radiation in order to accelerate NER. No study,
however, has tested the duration of treatment that is required prior to UV exposure
to accelerate NER in an in vivo setting. We next tested how far in advance the
mice required topical forskolin pretreatment in order for cAMP to accelerate NER.
Mice were pre-treated once a day with forskolin for 3 days, 1 day, or 1 hour prior
to exposure to 7.5 kJ/m2 UVB radiation. Repair of 6,4 PPs and CPDs was
assessed at 0, 16, and 24 hours following UV exposure. Pretreatment with topical
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Figure 4.6 cAMP Enhanced NER Kinetics In Vivo
A-B) Basal repair kinetics of 6,4 PPs (A) (n = 3 independent experiments)
and CPDs (B) (n = 3 indepndent experiments) in K14-Scf MC1R e/e mice.
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Data are expressed as mean percent 6,4 PP or CPD remaining ± SEM.
C-H) K14-Scf MC1R e/e mice (n=3 per group) were pre-treated for 1 hour
(C, D), 1 day (E, F), or 3 days (G, H) with a topical application of 70%
ethanol 30% propylene glycol or 10% forskolin in 70% ethanol 30%
propylene glycol prior to exposure to 7.5 kJ/m2 UVB. Kinetics of repair of
6,4 PPs (C, E, G) and CPDs (D, F, H) were assessed at 0, 16, and 24
hours following UV exposure. *p<0.05 forskolin compared to vehicle as
determined by two-way ANOVA. Data are expressed as mean percent
6,4 PP or CPD remaining ± SEM.
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forskolin for 1 hour did not accelerate NER kinetics for either 6,4 PPs or CPDs
(Figure 4.6 C, 4.6 D). Pretreatment with topical forskolin for 1 day accelerated the
NER kinetics for 6,4 PPs at 16 and 24 hours (Figure 4.6 E), however, there was
no benefit seen for CPDs (Figure 4.6 F). Pretreatment with topical forskolin for 3
days accelerated NER in both 6,4 PPs (16 hours) (Figure 4.6 G) and CPDs (24
hours) (Figure 4.6 H). Because CPDs have increased mutagenicity compared to
6,4 PPs (You Y et al., 2001), all subsequent DNA repair experiments were
performed using a 3 day forskolin pre-treatment.
To determine whether rapamycin affected the acceleration of NER following
treatment with forskolin, mice were shaved and treated with 70% propylene glycol
30% ethanol vehicle, 10 % forskolin in 70% propylene glycol 30% ethanol vehicle,
or a combination of 10% forskolin and 1% rapamycin in 70% propylene glycol 30%
ethanol vehicle for three days once a day prior to exposure to 7.5 kJ/m2 UVB
radiation. Repair of 6,4 PP and CPDs was assessed at 0, 16, and 24 hours
following UV exposure similar to previous experiments. Treatment with forskolin
significantly accelerated repair of 6,4 PP at 16 and 24 hours (Figure 4.7 A) and
CPDs at 24 hours (Figure 4.7 B), and simultaneous treatment with rapamycin did
not prevent the forskolin acceleration of repair (Figure 4.7 A and B). These data
further suggest it may be possible to activate the induction of eumelanin synthesis
and accelerate NER independent of cAMP induced proliferation.
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Figure 4.7 Rapamycin Does Not Prevent cAMP Enhanced NER Kinetics In
Vivo
A-B) K14-Scf MC1R e/e mice (n=5 per group) were pre-treated for 3 days
with a topical application of 70% ethanol 30% propylene glycol, 10%
forskolin or a combination of 10% forskolin and 1 % rapamycin prior to
exposure to 7.5 kJ/m2 UVB. Kinetics of repair of 6,4 PPs (A) and CPDs
(B) were assessed at 0, 16, and 24 hours following UV exposure. *p<0.05
forskolin compared to vehicle as determined by two-way ANOVA. Data
are expressed as mean percent 6,4 PP or CPD remaining ± SEM.
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4.4 Conclusions/Discussion
Activation of the MC1R signaling axis represents a major innate UV protective
mechanism to prevent and repair UV induced DNA damage. Pharmacologic
manipulation of MC1R signaling is a potential method to enhance the physiologic
protective pathways in individuals with both defective and intact MC1R signaling
to prevent UV induced skin cancers (Hauser et al., 2006; D’Orazio et al., 2006;
Khaled et al., 2010; Jarrett et al., 2014). Unregulated activation of cAMP signaling,
however, can lead to melanocyte proliferation with an increased potential for
malignant transformation (Suzuki et al., 1996; Kadekaro et al., 2003). In order for
pharmacologic manipulation of MC1R signaling to be a viable translational option,
it must be possible to selectively augment the two protective pathways without the
risk for proliferation. Herein we report that cAMP leads to activation of mTORC1,
that proliferation downstream of cAMP is sensitive to rapamycin in vitro and in vivo,
and that rapamycin treatment did not affect cAMP induced eumelanin synthesis or
enhancement of NER kinetics in vitro or in vivo.
We report that that the proliferation downstream of cAMP is a result of mTOR
signaling. cAMP accumulation leads to the activation of mTORC1 downstream of
PKA as evident by phosphorylation of mTOR at Ser2448 by p70S6K in an
mTORC1 dependent manner. Inhibition of mTORC2 did not affect cAMP induced
mTOR phosphorylation, and forskolin did not affect phosphorylation of Akt at
Ser371 suggesting cAMP signals in an mTORC2 independent manner. PKA did
not directly phosphorylate mTOR, Akt, or p70S6K suggesting PKA activates an
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additional regulatory component upstream of mTORC1. The activation of the
mTORC1 signaling pathway is complex and a result of numerous pathways
converging at the regulation of the mTORC1 inhibitors tuberous sclerosis 1 and
tuberin (TSC1/TSC2) (Laplante and Sabatini, 2012). One of the major pathways
which regulates TSC1/TSC2 activity is the phopshoinositide 3 kinase (PI3K)/Akt
pathway. Activation of Akt downstream of PI3K dishinibits mTORC1 via an
inhibition of TSC1/TSC2 (Manning et al., 2002). Recent data reports that MC1R
activation leads to an increase in the PI3K inhibitor phosphatase and tensin
homolog (PTEN) function and a subsequent inhibition of PI3K/Akt signaling (Cao
et al., 2013). Increased PTEN levels would theoretically have an effect of
decreasing mTOR signaling due to inhibition of the PI3K/Akt cascade. We
hypothesize, therefore, that MC1R activation of mTOR occurs via a different
mechanism.
Our data suggest that activation of proliferation can be independently inhibited
while maintaining the UV protective pathways downstream of cAMP. We
demonstrated that through a combination of pharmacologic drugs to activate cAMP
signaling downstream of MC1R (forskolin) and prevent cAMP induced proliferation
(rapamycin) it was possible to selectively augment the cAMP dependent UV
protective pathways. Treatment with rapamycin did not prevent forskolin induction
of eumelanin synthesis or acceleration of NER, and in fact, the combination of
forskolin and rapamycin led to an increase in pigment enzyme expression above
that of forskolin alone in vitro. A similar effect was not seen in vivo, and it is possible
that the combination of forskolin and rapamycin did not further augment protein
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levels of pigment associated enzymes. It is possible, however, that higher
concentrations of rapamycin could promote pigment synthesis in the mouse model,
or that UV exposure could be required for an increase in pigment production
downstream of rapamycin. Tacrolimus, a macrolide immunosuppressant similar to
rapamycin, has been shown to increase the eumelanin levels in melanocytes and,
following UVB exposure, facilitate the transfer of melanosomes from melanocytes
to keratinocytes (Jung et al., 2016). Topical tacrolimus has been used to promote
repigmentation in patients with vitiligo. Both rapamycin and tacrolimus bind to the
FK-binding protein 12 (FKBP12), however, the rapamycin-FKBP12 complex
inhibits mTOR while the tacrolimus-FKBP12 complex inhibits calcinuerin. Despite
their differing mechanisms of action, both tacrolimus and rapamycin function to
decrease IL-2 levels. It is possible that either the effect on cytokine signaling or the
complex with between tacrolimus or rapamycin and FKBP12 could affect
pigmentation.
In addition to demonstrating that proliferation was independently regulated from
pigmentation and NER, we determined that a 3-day pretreatment was required in
vivo to accelerate NER kinetics of CPDs. The acceleration of 6,4 PPs, however,
occurred after both the 1-day and 3-day pretreatment with forskolin. We previously
demonstrated that acceleration of NER downstream of cAMP is dependent upon
ATR phosphorylation by PKA and the subsequent recruitment of XPA to sites of
photodamage by ATR (Jarrett et al., 2014). 6,4 PPs cause a larger distortion to the
DNA helix and are more easily recognized and repaired. It is possible, therefore,
that the ATR/XPA complex preferentially recognize sites of 6,4 PPs before CPDs.
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Because CPDs are more mutagenic than 6,4 PPs, however, it would be necessary
to accelerate their repair to see a therapeutic benefit.
In summary, our data have direct translational relevance. We have determined in
mice that a minimum of 3-day forskolin pretreatment prior to UV exposure is
required for the acceleration of NER, suggesting a multi-day treatment will also be
required in humans. In addition, the combination treatment of forskolin and
rapamycin demonstrates a proof of principle that it is possible to selectively
augment the UV protective pathways downstream of MC1R without the risk of
proliferation suggesting augmentation of the MC1R pathway may be a viable
translational option to prevent melanoma development.
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________________________________________________________________
Chapter 5: Overall Conclusions, Limitations, Future Studies, and Summary
________________________________________________________________
5.1 Overall Conclusions
The melanocortin 1 receptor (MC1R) signaling axis is a major innate defense
mechanism to protect against ultraviolet (UV) radiation induced skin cancer,
particularly melanoma. Activation of the receptor by its positive agonist, α
melanocyte stimulating hormone (αMSH), leads to the induction of eumelanin
synthesis (Suzuki et al., 1997) (Figure 1.7) and the acceleration of nucleotide
excision repair (NER) (Hauser et al., 2006; Kadekaro et al., 2012; Jagirdar et al.,
2013) (Figure 1.4, Figure 1.8) to prevent and repair UV induced DNA damage
respectively. Individuals with loss-of-function mutations in MC1R typically have fair
skin, exhibit increased sun sensitivity, and are at an increased risk for developing
UV induced melanoma due to loss of the UV protective pathways (Valverde et al.,
1995). Pharmacologic manipulation of MC1R signaling is a potential mechanism
to augment the UV protective signaling pathways in individuals with loss-offunction mutations in MC1R (Abdel-Malek et al., 2006; D’Orazio et al., 2006;
Khaled et al., 2010; Jarrett et al., 2014). In addition to promoting UV protective
pathways, however, MC1R signaling also promotes melanocyte proliferation
(Suzuki et al., 1996; Kadekaro et al., 2003). Unregulated MC1R activation,
therefore, could lead to uncontrolled melanocyte proliferation increasing the
potential for malignant transformation. The overall goal of this dissertation is to
122

further elucidate the complexities of MC1R signaling, specifically to assess the
interdependence of the pigmentation, NER, and proliferation pathways to
determine whether any one pathway could be selectively augmented or inhibited
in a translationally relevant manner.
MC1R signaling is controlled via three endogenous ligands, the positive agonist
αMSH (Abdel-Malek et al., 2000), the neutral antagonist β-defensin 3 (βD3)
(Candille et al., 2007), and the negative agonist agouti signaling protein (ASIP)
(Blanchard et al., 1995). Understanding the regulation of these ligands following
UV exposure is important to better understand how MC1R signaling is
physiologically controlled. The ligands function in a competitive manner as binding
of MC1R to any ligand is mutually exclusive (Ollmann et al., 1998; Swope et al.,
2012; Nix et al., 2013). Therefore, binding of ASIP (Blanchard et al., 1995) or βD3
(Candille et al., 2007) to MC1R prevents activation of MC1R via αMSH.
Although the regulation of αMSH expression is well characterized and known to
be dependent upon UV damage (Cui et al., 2007), the regulation of βD3,
specifically following UV exposure, is not entirely understood. We previously
demonstrated that binding of βD3 to MC1R prevented αMSH induced acceleration
of NER in a dose dependent manner (Jarrett et al. 2015) suggesting that increased
levels of βD3 in the skin would negatively correlate with αMSH induced MC1R
signaling. It is therefore important to understand how βD3 expression is regulated
in the skin. In Chapter 2, we demonstrated that UV radiation of ex vivo human
whole skin explants was not sufficient to cause an increase in βD3 expression,
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however, an in vivo study utilizing human volunteers, demonstrated that βD3
expression was induced following UV radiation (Glaser et al., 2009). Taken
together, these studies suggest that βD3 induction following UV is not dependent
upon DNA damage as documented for αMSH, and that there are additional factors
regulating βD3 expression. βD3 is canonically studied for its role in the immune
response and has been shown to be induced by multiple cytokines including tumor
necrosis factor α (TNFα) and interleukin-1β (IL-1β) (Harder et al., 2001) during
pathological situations of sustained inflammation such as wound healing (Kesting
et al., 2010). UV induced sunburns also lead to a high degree of inflammation and
similar cytokine induction as wound healing, including TNFα (Schwarz et al., 1995)
and IL-1β (Faustin and Reed, 2008), and it is possible that the inflammation
associated with UV exposure is required to increase βD3 levels in the skin.
The induction of βD3 following inflammation demonstrates the importance for
MC1R signaling augmentation in individuals not only with loss of function MC1R
but specifically with wild-type MC1R. Elevated βD3 levels due to cytokine signaling
following a sunburn would greatly affect MC1R function because βD3 would
prevent αMSH activation of MC1R (Swope et al., 2012; Jarrett et al. 2015). UV
exposure to skin that does not result in sunburn theoretically would induce αMSH
without a concomitant induction of βD3 and would result in MC1R activation. UV
exposure that resulted in a sunburn, however, theoretically would lead to the
induction of both αMSH and βD3 which would compete for binding to MC1R. We
demonstrated that βD3 expression correlated with TNFα expression (Figure 2.5),
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therefore, we hypothesize that βD3 induction would positively correlate with the
degree of sunburn resulting in increased competition for αMSH binding to MC1R.
Taken together, these data suggest that an individual with wild-type MC1R who
has sustained a sunburn with inflammation will phenotypically resemble an
individual with loss-of-function MC1R due to elevated levels of βD3 which will
compete with and prevent αMSH binding to MC1R. These individuals would have
a decreased ability to induce eumelanin synthesis and will have similar NER
kinetics as an individual who has a non-functional MC1R protein emphasizing the
importance for MC1R signaling augmentation in all individuals.
Although pharmacologic bypass of MC1R regulation would augment MC1R
signaling in all individuals regardless of their MC1R status or degree of
inflammation following UV exposure, unregulated MC1R activation would promote
melanocyte proliferation with the increased potential for malignant transformation.
Selective induction of eumelanin synthesis and the acceleration of NER without
the risk of proliferation would be ideal and suggests the importance of
understanding the interdependence of the three pathways downstream of MC1R.
All three pathways result from cAMP accumulation and activation of protein kinase
A (PKA), however, they appear to diverge downstream of PKA (eumelanin
synthesis – micropthalmia-associated transcription factor (MITF) dependent; NER
enhancement – ataxia telangiectasia and Rad3 related protein (ATR) dependent;
proliferation – mechanistic target of rapamycin (mTOR) dependent) suggesting
they could be independently regulated. One therapeutic possibility would be to
utilize a combination of pharmacologic drugs to 1) augment MC1R activity and 2)
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selectively prevent the proliferative response to prevent an increase. In Chapter 4,
we demonstrated that cAMP induced proliferation is sensitive to rapamycin, an
inhibitor of mTOR signaling (Figure 4.3, Figure 4.5). We also demonstrated that a
combination of forskolin (induce MC1R activity) and rapamycin (Figure 5.1)
functioned as a proof of concept to augment the protective pathways without the
risk of proliferation as rapamycin treatment did not prevent the induction of
eumelanin synthesis nor the acceleration of NER downstream of cAMP in vitro
(Figure 4.4) or in vivo (Figure 4.5 and Figure 4.7).
In Chapter 4, we demonstrated that cAMP signaling led to an increase in mTORC1
signaling in a PKA dependent manner (Figure 4.1 and Figure 4.2), however, we
did not specifically determine the mechanism by which cAMP induces mTOR
function. There are multiple pathways to augment mTORC1 signaling, and we
hypothesize the mTOR activation immediately following cAMP stimulus occurs in
a glycogen synthase kinase-3β (GSK3β) dependent manner (Figure 5.2). GSK3β
acts as an inhibitor of mTORC1 by phosphorylating and activating the mTORC1
inhibitor complex of tuberous sclerosis 1/tuberin (TSC1/TSC2) (Inoki et al., 2006).
MC1R activation has been shown to inhibit GSK3β via phosphorylation of GSK3β
by PKA at Ser9 (Bellei et al., 2011). Inhibition of GSK3β would prevent activation
of TSC1/TSC2 and result in a disinhibition of mTORC1 signaling. In addition,
MC1R could lead to mTORC1 activation via elevated MITF levels and sustained
inhibition of GSK3β via Wnt via an undetermined mechanism (Ploper et al., 2015).
MITF and Wnt exist in a positive feedback loop as MITF stabilizes Wnt levels
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Figure 5.1 Pharmacologic Modulation of the MC1R UV Protective
Pathways
MC1R signaling activates three distinct pathways downstream of cAMP
accumulation and PKA activation: 1) the induction of eumelanin
synthesis via CREB and MITF signaling, 2) the acceleration of nucleotide
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synthesis via CREB and MITF signaling, 2) the acceleration of nucleotide
excision repair (NER) via ATR signaling, and 3) activation of melanocyte
proliferation via mTOR signaling. A combination of forskolin (an activator
of adenylyl cyclase) and rapamycin (an inhibitor of mTOR) treatment
results in the selective activation of the two UV protective pathways
downstream of cAMP without the risk of melanocyte proliferation.
Abbreviations: ATR – ataxia telangiectasia mutated and Rad3 related;
CREB – cAMP responsive binding element; MC1R – melanocortin 1
receptor; mTOR – mechanistic target of rapamycin; PKA – protein kinase
A
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Figure 5.2 Activation of mTORC1 Downstream of cAMP
MC1R signaling results in the activation of adenylyl cyclase and the
accumulation of cAMP. cAMP activates PKA which then activates
mTORC1 signaling and leads to p70S6K phosphorylation of mTOR at
Ser2448. mTORC1 activation results in melanocyte proliferation. We
hypothesize that PKA activation of mTORC1 initially occurs downstream
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hypothesize that PKA activation of mTORC1 initially occurs downstream
of GSK3β. PKA phosphorylates GSK3β inhibiting its kinase function.
GSK3β functions to activate the mTORC1 inhibitors TSC1/TSC2 via
phosphorylation. Inhibition of GSK3β results in a disinhibition of
mTORC1 activity. We also hypothesize that elevated MITF levels
downstream of cAMP result in sustained mTORC1 function. MITF
stabilizes Wnt levels preventing its degradation, and Wnt can inhibit
GSK3β kinase function further disinhibiting mTORC1.
Abbreviations: DEPTOR – DEP domain containing mTOR-interacting
protein; GSK3β - glycogen synthase kinase 3β; MC1R – melanocortin 1
receptor; mLST8 – mammalian lethal with sec-13 protein 8; mTOR –
mechanistic target of rapamycin; mTORC1 - mechanistic target of
rapamycin complex 1; PKA – protein kinase A; PRAS40 – proline-rich
Akt substrade 40 kDa; TSC1 – tuberous sclerosis 1; TSC2 – tuberin

130

preventing it from being degraded, and Wnt in turn stabilizes MITF (Rodriguez and
Setaluri, 2014). Wnt signaling also leads to an inhibition of GSK3β resulting in a
disinhibition of mTORC1 activation (Inoki et al., 2006). Therefore, immediate
activation of mTORC1 following cAMP stimulus could result from PKA inhibition of
GSK3β, and sustained proliferation could result from MC1R induced MITF
expression and the subsequent stabilization of Wnt by MITF resulting in inhibition
of GSK3β (Figure 5.2).
The fact that MITF may play a role in MC1R induced proliferation highlights the
importance of understanding the interaction of the three pathways downstream of
MC1R as MITF is also important for eumelanin synthesis. In Chapter 3, we
determined that the interaction between the two protective pathways downstream
of MC1R appears to be complex and may have a degree of interdependence at
the level of ATR but not MITF. We demonstrated that MITF was not required for
ATR dependent acceleration of NER kinetics downstream of MC1R (Figure 3.1
and 3.2). MITF functions as a global transcription factor and does regulates gene
expression involved in both eumelanin synthesis (Levy et al., 2006) and NER
(Strub et al., 2011). MITF induces expression of RPA and POLE (Strub et al.,
2011). Neither protein, however, affects the rate of NER as the rate limiting step of
NER is at the level of XPA. Because MITF does not regulate XPA gene expression,
it is not surprising that inhibition of MITF did not affect the kinetics of NER. MC1R
activation not only increases the kinetics of NER, but also leads to a decrease in
mutagenesis (Jarrett et al., 2014). Because MITF does promote the expression of
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genes involved in NER, it is possible that MITF may affect fidelity of NER and
inhibition of MITF may lead to an increase in mutagenesis independent of kinetics.
ATR is a serine/threonine kinase and functions in response to both replication
stress and UV induced DNA damage (Cimprich and Cortez, 2008). Our data
suggest that inhibition of ATR kinase function does not affect PKA phosphorylation
of cAMP responsive binding element (CREB) (Figure 3.3, 3.5), however, it does
prevent induction of Mitf and MITF induction of genes involved in eumelanin
synthesis (Figure 3.6). Thus far, ATR has not been shown to play a role in nuclear
transcription, however, it does function at the level of DNA to regulate both
replication stress and the DNA damage response. During situations of replication
stress and DNA damage, ATR recognizes and binds to a common structural
theme: sites of single stranded DNA bound with replication protein A (RPA) and
ATR interacting protein (ATRIP). Evidence suggests that RPA is bound to ssDNA
in transcription loops (Chaudhuri et al., 2004) suggesting ATR could also have the
potential to bind to and stabilize the open conformation in transcription as it does
in both replication stress and NER.
Although our data are consistent with ATR playing a role in global transcription
regulation, our evidence does not preclude the possibility that ATR directly affects
MITF function instead. Ataxia telangiectasia mutated (ATM) protein, an additional
member of the PIKK family and a close relative to ATR, has been shown to directly
phosphorylate CREB (Shi et al., 2004; Dodson and Tibbetts, 2006) which is
responsible for the induction of Mitf expression, however, a similar phosphorylation
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event has not been shown for ATR. To our knowledge, neither ATR nor ATM has
been shown to directly phosphorylate MITF. The effect of ATR on Mitf transcription,
therefore, may be due to a direct interaction of ATR and MITF, however, it is highly
probably that ATR plays an additional role in the cell and affects transcription
stability by binding to RPA coated ssDNA in transcription loops.
It should be noted that the experiments in Figure 3.3, Figure 3.4, and Figure 3.6
were conducted following cAMP stimulus alone without UV exposure. We have
demonstrated that ATR kinase function is activated following UV radiation (Jarrett
et al., 2014). ATR kinase activity, however, is not dependent upon UV radiation or
DNA damage as is found in situations of replication stress. Instead, ATR activation
requires binding of ATR to ATRIP (Cimprich and Cortez, 2008). Therefore, if
ATRIP can interact with RPA coated ssDNA in transcription loops, it is possible
that is sufficient to increase ATR activity. In addition, our studies did not address
protein changes associated with the pigment genes, and it is possible that ATR
function may affect transcription but does not affect the pigment protein levels, and
therefore does not play a role in eumelanin synthesis.
5.2 Limitations
5.2.1 Neonatal Skin Explants
Although we do not anticipate that gender would play a role in MC1R signaling and
regulation, there is a potential for gender bias in our results in Chapter 2 as all of
the neonatal skin explants were derived from discarded foreskin tissue and are
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therefore all from male subjects. In addition, the foreskins were collected over a
few months’ time period, and the circumcisions were performed by multiple
individuals with varying techniques and experience. We cannot exclude that the
variations in βD3 induction were dependent upon different removal procedures.
We also predict that the samples were UV naïve, however, because they were deidentified, it is possible that the infants received light therapy for various medical
conditions including jaundice prior to circumcision. There are also situations which
preclude an infant from being circumcised immediately after birth, and samples
could have come from infants who were past the neonate age. Finally, the skin
samples were collected daily, however, the time in media prior to processing varied
from 0-4 hours which could have affected our results.
An alternative approach using skin biopsies collected from individuals undergoing
plastic surgery (i.e. breast reduction or abdominoplasty) would provide skin
samples from both males and females. Collecting biopsies from plastic surgery
would provide skin samples from adults, and it would be difficult to control for
whether the skin had been exposed to UV radiation.
5.2.2 Primary Human Melanocyte Cell Lines
The primary human melanocyte cell lines utilized were derived from male foreskin
samples, therefore, our cell culture results in Chapter 3 may have a gender bias
similar to the neonatal skin explants. In order to control for a gender bias, future
experiments could be performed in primary human melanocyte cell lines isolated
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from skin biopsies collected from plastic surgeries as mentioned above which
could be taken from both males and females.
5.2.3 SK-MEL-2 Transformed Melanoma Cell Line
The biochemistry experiments conducted in Chapter 4 were performed exclusively
in a transformed melanoma cell line. Transformed malignant cells have altered
properties and signaling compared to their non-malignant cell counterparts. mTOR
signaling, specifically, is often altered and upregulated in transformed cells. In
addition, the experiments revolve around induction of protective pathways to
prevent melanoma development. The experiments could be repeated in multiple
transformed melanoma cell lines to ensure that the results were not cell line
specific. In addition, the experiments would need to be repeated in primary human
melanocytes to demonstrate that the protective pathways could be induced in
normal, non-transformed cells.
5.2.4 Murine Model
Melanocytes in non-transgenic mouse skin migrate down through the dermis into
the hair follicle as the animal develops rather than remaining near the interfollicular
junction as in human skin. The cKit-SCF transgenic mice with humanized skin
naturally retain the melanocytes at birth, but after weaning, the melanocytes also
migrate away from the epidermis. Topical treatment with forskolin results in
melanocyte retention in the epidermis, however, it is unclear whether the
melanocytes are dividing or simply not migrating. Therefore, the mice may be an

135

inappropriate model to study melanocyte proliferation and other models such as
the MH19 murine model which better retains the melanocytes throughout its
lifetime should be used in future studies.
The NER experiments conducted in the cKit-SCF transgenic mice with mutated
Mc1r (Mc1r

e/e

) were done on whole skin biopsies, and the results are therefore

not melanocyte specific. A majority of cells in skin are of a non-melanocyte origin,
and therefore, it is not possible to make conclusions specific to melanocyte biology
utilizing whole skin.
5.3 Future Directions
Future directions will focus on three main goals: 1) better understanding the
regulation of βD3 following UV radiation, 2) determining the mechanism of cAMP
induction of mTOR signaling, and 3) translational applications.
5.3.1 βD3 Regulation
Future studies will further clarify the role of UV exposure on the induction of βD3.
In vivo studies demonstrated that exposure of human skin to UV radiation resulted
in βD3 mRNA induction (Glaser et al., 2009), however, in Chapter 2, our data
suggest that UV radiation alone was insufficient for βD3 induction in ex vivo human
skin explants. We hypothesize that the discrepancy in the results lies in the lack of
a physiologically intact immune system in the ex vivo explants. A combination of
cell culture and in vivo human studies would best elucidate whether inflammation
associated with UV exposure is required for βD3 induction.
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Primary human keratinocytes could be cultured independently to confirm whether
UV damage alone causes induction of βD3. In addition, primary human
keratinocytes could be co-cultured with primary human melanocytes in a transwell
apparatus prior to UV exposure to determine whether UV induces a factor from
melanocytes necessary for βD3 induction. We hypothesize that UV treatment
alone would not induce βD3 expression in vitro due to lack of cytokine induction.
Although UV treatment has been shown to induce TNFα production in
keratinocytes (Schwarz et al. 1999; An et al., 2010), the degree of induction may
not be enough in vitro to induce βD3.
In vivo experiments utilizing UV exposure of human skin would further confirm
whether the immune system is required. Human skin which is not normally
exposed to UV radiation (i.e. the buttocks region) would be ideal for experiments.
Small regions of skin from each individual could be exposed to multiple doses of
UV to determine whether increased UV exposure correlated with βD3 induction
and cytokine induction.
Thus far no studies have demonstrated that the murine βD3 homolog functions as
the human βD3 with respect to MC1R. If experiments could demonstrate that the
murine βD3 homolog could bind to MC1R and affect its function, it would be
possible to test whether increased UV exposure would affect βD3 levels and MC1R
function, specifically accelerated NER kinetics. Mice with a wild-type and mutant
MC1R protein could be exposed to increasing doses of UV radiation and NER
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kinetics compared over time. If the murine βD3 can bind to MC1R and prevent
αMSH from binding to MC1R, we hypothesize that increased exposure of UV
radiation would result in 1) increased cytokine production, 2) increased βD3
production, and 3) prevention of αMSH acceleration of NER in mice with a wildtype MC1R.
5.3.2 cAMP and mTOR Mechanism
In Chapter 4, we demonstrated that mTORC1 was activated following cAMP
accumulation, however, we did not determine the mechanism by which cAMP
induced mTORC1 activity. mTOR is regulated via numerous pathways many of
which converge on the mTORC1 inhibitors TSC1/TSC2 (Laplante and Sabatini,
2012). Because PKA has been shown to inhibit GSK3β, an activator of
TSC1/TSC2 (Inoki et al., 2006), we hypothesize that mTORC1 activation
immediately downstream of MC1R is a result of GSK3β inhibition. We would first
assess whether cAMP accumulation increased GSK3β phosphorylation at Ser9 in
a PKA dependent manner. We would next test whether GSK3β dependent
phosphorylation of TSC2 on Ser1371, Ser1375, Ser1379, and Ser1383 was
altered downstream of cAMP.
GSK3β function can also be inhibited by Wnt signaling (Inoki et al., 2006). Because
MITF has been shown to stabilize Wnt levels, we hypothesize that increased MITF
levels downstream of MC1R activation would stabilize Wnt levels resulting in
GSK3β inhibition and sustained mTORC1 activation and proliferation. We would
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first test the duration of mTORC1 activation downstream of MC1R and assess
GSK3β phosphorylation of TSC1/TSC2. Finally, we directly test the role of MITF in
sustained mTORC1 activation and determine whether MITF knockout affected
mTORC1 function and GSK3β phosphorylation of the TSC1/TSC2 complex.
5.3.3 Translational Approach
Chapter 4 demonstrates a proof of concept that it is possible to selectively enhance
the MC1R protective pathways without the risk of proliferation via a combination of
pharmacologic drugs. Although topical applications of rapamycin have been used
therapeutically in disease states including tuberous sclerosis with few
complications (Wataya-Kaneda et al., 2011), rapamycin is an immunosuppressant
and there are risk factors associated with using rapamycin for extended periods of
time including elevated levels of infection and metabolic alterations (Salmon,
2015). In addition, there are risk factors associated with global increased cAMP
levels as would be found following treatment with either forskolin or rolipram rather
than the selective activation of cAMP in melanocytes following treatment with a
melanocortin analog. cAMP functions as a second messenger in smooth muscle
cells causing relaxation. Elevated levels of systemic cAMP would result in
decreased blood pressure from blood vessel dilation and constipation from
inhibition of peristalsis.
We demonstrated that mice required a minimum of a three-day pre-treatment with
forskolin prior to UV exposure to see an acceleration of NER. Mouse skin is much
thinner than human skin, and theoretically, human skin would require a longer
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duration prior to UV exposure for the drug to absorb to levels necessary to see
beneficial effects in addition to continued treatment for the duration of UV
exposure. Therefore, individuals would require prolonged exposure to a
forskolin/rapamycin treatment with the consequence of elevated global cAMP
levels and immunosuppression. There are psychosocial components to a
prolonged treatment regiment, in addition to the side effects, as patient medication
compliance is a concern (Brown and Bussell, 2011), and patient compliance
decreases with complexity of medication (Jin et al., 2008). Future studies,
therefore, could focus on three concepts: 1) identifying melanocyte specific targets
to augment cAMP such that there is diminished systemic side effects, 2) better
characterizing MC1R induced proliferation to identify a novel target to inhibit, and
3) developing a more potent treatment to minimize complexity and maximize
potential patient compliance.
5.4 Summary
In summary, the overall goal of this dissertation was to better characterize the
complexities of MC1R signaling, and to specifically assess the interdependence of
the pigmentation, NER, and proliferation pathways to determine whether they
could be manipulated in a translationally relevant manner. We have determined
that βD3 expression is not induced following UV radiation, however, it correlates
with cytokine induction (Chapter 2). We have also determined that ATR but not
MITF may play a role in both eumelanin synthesis and NER (Chapter 3). Finally,
we demonstrated that cAMP induced proliferation is a result of mTORC1 signaling
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and demonstrated that selective activation of the UV protective pathways
downstream of cAMP is possible without the risk of proliferation via a combination
therapy of forskolin and rapamycin (Chapter 4).

Copyright © Erin Marissa Wolf Horrell 2016
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The author retains copyright of materials published in F1000Research and
Frontiers in Genetics and by the InTech publishing group. Documents are
distributed under the Creative Commons Attribution-NonCommercial 4.0
International which permits users to copy, redistribute, and adapt the material in
any format.
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